[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

CA2124967A1 - Transgenic non-human animals capable of producing heterologous antibodies - Google Patents

Transgenic non-human animals capable of producing heterologous antibodies

Info

Publication number
CA2124967A1
CA2124967A1 CA002124967A CA2124967A CA2124967A1 CA 2124967 A1 CA2124967 A1 CA 2124967A1 CA 002124967 A CA002124967 A CA 002124967A CA 2124967 A CA2124967 A CA 2124967A CA 2124967 A1 CA2124967 A1 CA 2124967A1
Authority
CA
Canada
Prior art keywords
human
transgenic
antibodies
human animals
endogenous
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002124967A
Other languages
French (fr)
Other versions
CA2124967C (en
Inventor
Nils Lonberg
Robert M. Kay
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genpharm International Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US07/810,279 external-priority patent/US5569825A/en
Priority claimed from US07/853,408 external-priority patent/US5789650A/en
Application filed by Individual filed Critical Individual
Publication of CA2124967A1 publication Critical patent/CA2124967A1/en
Application granted granted Critical
Publication of CA2124967C publication Critical patent/CA2124967C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0276—Knock-out vertebrates
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2812—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3007—Carcino-embryonic Antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
    • C07K16/4291—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig against IgE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/01—Animal expressing industrially exogenous proteins
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A01K2267/0381—Animal model for diseases of the hematopoietic system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Environmental Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Animal Husbandry (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

The invention relates transgenic non-human animals capable of producing heterologous antibodies and transgenic non--human animals having inactivated endogenous immunoglobulin genes. In one aspect of the invention, endogenous immunoglob-ulin genes are suppresed by antisense polynucleotides and/or by antiserum directed against endogenous immunoglobulins.
He-terologous antibodies are encoded by immunoglobulin genes not normally found in the genome of that species of non-human animal. In one aspect of the invention, one or more transgenes containing sequences of unrearranged heterogolous human immu-noglobulin heavy chains are introduced into a non-human animal thereby forming a transgenic animal capable of functionally rearranging transgenic immunoglobulin sequences and producing a repertoire of antibodies of various isotypes encoded by hu-man immunoglobulin genes. Such heterologous human antibodies are produced in B-cells which are thereafter immortalized, e.g., by fusing with an immortalizing cell line such as a myeloma or by manipulating such B-cells by other techniques to perpetuate a cell line capable of producing a monoclonal heterologous antibody. The invention also relates to heavy and light chain immunog-lobulin transgenes for making such transgenic non-human animals as well as methods and vectors for disrupting endogenous im-munogiobulin loci in the transgenic animal.
CA002124967A 1991-12-17 1992-12-17 Transgenic non-human animals capable of producing heterologous antibodies Expired - Lifetime CA2124967C (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US07/810,279 US5569825A (en) 1990-08-29 1991-12-17 Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US07/810,279 1991-12-17
US07/853,408 US5789650A (en) 1990-08-29 1992-03-18 Transgenic non-human animals for producing heterologous antibodies
US07/853,408 1992-03-18
US90406892A 1992-06-23 1992-06-23
US07/904,068 1992-06-23
PCT/US1992/010983 WO1993012227A1 (en) 1991-12-17 1992-12-17 Transgenic non-human animals capable of producing heterologous antibodies

Publications (2)

Publication Number Publication Date
CA2124967A1 true CA2124967A1 (en) 1993-06-24
CA2124967C CA2124967C (en) 2008-04-08

Family

ID=27420056

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002124967A Expired - Lifetime CA2124967C (en) 1991-12-17 1992-12-17 Transgenic non-human animals capable of producing heterologous antibodies

Country Status (5)

Country Link
EP (1) EP0746609A4 (en)
JP (2) JPH07503132A (en)
AU (1) AU3328493A (en)
CA (1) CA2124967C (en)
WO (1) WO1993012227A1 (en)

Families Citing this family (775)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6713610B1 (en) 1990-01-12 2004-03-30 Raju Kucherlapati Human antibodies derived from immunized xenomice
US7041871B1 (en) 1995-10-10 2006-05-09 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US7084260B1 (en) 1996-10-10 2006-08-01 Genpharm International, Inc. High affinity human antibodies and human antibodies against human antigens
US5770429A (en) * 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
AU6819494A (en) * 1993-04-26 1994-11-21 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5827690A (en) * 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
US5885574A (en) 1994-07-26 1999-03-23 Amgen Inc. Antibodies which activate an erythropoietin receptor
IL117175A (en) 1995-02-20 2005-11-20 Sankyo Co Osteoclastogenesis inhibitory factor protein
US6130364A (en) * 1995-03-29 2000-10-10 Abgenix, Inc. Production of antibodies using Cre-mediated site-specific recombination
AU4376400A (en) * 1995-04-27 2000-11-30 Abgenix, Inc. Human antibodies derived from immunized xenomice
AU2008202860B9 (en) * 1995-04-27 2012-03-29 Amgen Fremont Inc. Human Antibodies Derived From Immunized Xenomice
CA2761116A1 (en) * 1995-04-27 1996-10-31 Amgen Fremont Inc. Human antibodies derived from immunized xenomice
US5783186A (en) 1995-12-05 1998-07-21 Amgen Inc. Antibody-induced apoptosis
US6537776B1 (en) 1999-06-14 2003-03-25 Diversa Corporation Synthetic ligation reassembly in directed evolution
WO1997033617A1 (en) * 1996-03-13 1997-09-18 Protein Design Labs, Inc. Fas ligand fusion proteins and their uses
EP1854481B1 (en) 1996-04-23 2014-07-16 Chugai Seiyaku Kabushiki Kaisha Cerebral stroke/cerebral edema preventive or remedy containing IL-8 binding inhibitor as active ingredient
US5961976A (en) * 1996-06-03 1999-10-05 United Biomedical, Inc. Antibodies against a host cell antigen complex for pre- and post-exposure protection from infection by HIV
DK0942968T3 (en) 1996-12-03 2008-06-23 Amgen Fremont Inc Fully human antibodies that bind EGFR
IL130492A (en) 1996-12-23 2007-09-20 Immunex Corp Antibodies to a receptor activator of nf-kappa b ligand (rankl), methods of preparing the antibodies and compositions comprising them
EP2322216A1 (en) 1997-03-21 2011-05-18 Chugai Seiyaku Kabushiki Kaisha A preventive or therapeutic agent for sensitized T cell-mediated diseases comprising IL-6 antagonist as an active ingredient
ATE328006T1 (en) 1997-04-15 2006-06-15 Sankyo Co NEW PROTEIN AND METHOD FOR THE PRODUCTION THEREOF
US5843678A (en) * 1997-04-16 1998-12-01 Amgen Inc. Osteoprotegerin binding proteins
US6316408B1 (en) 1997-04-16 2001-11-13 Amgen Inc. Methods of use for osetoprotegerin binding protein receptors
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
GB9711167D0 (en) * 1997-05-31 1997-07-23 Babraham The Inst Telomere-associated chromosome fragmentation
DE69839517D1 (en) 1997-08-15 2008-07-03 Chugai Pharmaceutical Co Ltd PREVENTIVA OR ARZNEIA CONTAINING NEUTRALIZING ANTI-IL6 RECEPTOR ANTIBODIES FOR REDUCING URINARY PROTEINS IN SYSTEMIC LUPUS ERYTHEMATOSUS
EP1015633A1 (en) * 1997-09-19 2000-07-05 Laboratories Inc. Medelys Method and kit for early diagnosis of autoimmunity and lymphoma in central nervous system
CA2251263A1 (en) * 1997-11-14 1999-05-14 Hajime Karasuyama Transgenic animal allergy models and methods for their use
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
TWI239847B (en) * 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US7179892B2 (en) 2000-12-06 2007-02-20 Neuralab Limited Humanized antibodies that recognize beta amyloid peptide
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
BRPI9916853B8 (en) 1998-12-23 2021-05-25 Abgenix Inc monoclonal antibody or an antigen-binding fragment thereof that specifically binds to cytotoxic t-lymphocyte antigen 4 (ctla-4) and nucleic acid
US6682736B1 (en) 1998-12-23 2004-01-27 Abgenix, Inc. Human monoclonal antibodies to CTLA-4
US7109003B2 (en) 1998-12-23 2006-09-19 Abgenix, Inc. Methods for expressing and recovering human monoclonal antibodies to CTLA-4
EP1604997A1 (en) * 1999-02-05 2005-12-14 Therapeutic Human Polyclonals, Inc. Human polyclonal antibodies from transgenic nonhuman animals
JP5694623B2 (en) * 1999-02-05 2015-04-01 セラピューティック ヒューマン ポリクローナルズ， インコーポレイテッド Human polyclonal antibodies obtained from genetically engineered animals
JP4488579B2 (en) * 1999-03-30 2010-06-23 日本たばこ産業株式会社 Method for producing monoclonal antibody
AU754808B2 (en) * 1999-03-30 2002-11-28 Amgen Fremont Inc. Method for preparing Monoclonal Antibody
US6864235B1 (en) 1999-04-01 2005-03-08 Eva A. Turley Compositions and methods for treating cellular response to injury and other proliferating cell disorders regulated by hyaladherin and hyaluronans
US6911429B2 (en) 1999-04-01 2005-06-28 Transition Therapeutics Inc. Compositions and methods for treating cellular response to injury and other proliferating cell disorders regulated by hyaladherin and hyaluronans
WO2004009618A2 (en) 2002-07-18 2004-01-29 Crucell Holland B.V. Recombinant production of mixtures of antibodies
UA81216C2 (en) 1999-06-01 2007-12-25 Prevention and treatment of amyloid disease
US6833268B1 (en) * 1999-06-10 2004-12-21 Abgenix, Inc. Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions
TWI290832B (en) 1999-08-23 2007-12-11 Chugai Pharmaceutical Co Ltd Expression enhancer for HM1.24 antigen
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
EP1212422B1 (en) 1999-08-24 2007-02-21 Medarex, Inc. Human ctla-4 antibodies and their uses
AU6871900A (en) 1999-09-06 2001-04-10 Chugai Seiyaku Kabushiki Kaisha Tsg-like gene
EP1486510B1 (en) 1999-09-21 2009-05-13 Chugai Seiyaku Kabushiki Kaisha Use of transporter gene oatp-c to screen for test compounds
CZ20021035A3 (en) 1999-10-01 2002-08-14 Chugai Seiyaku Kabushiki Kaisha Prophylaxis and treatment of diseases connected with disorder of blood sedimentation rate
US8029793B2 (en) 2000-04-28 2011-10-04 Chugai Seiyaku Kabushiki Kaisha Methods for inhibiting cell proliferation
DK2026073T3 (en) 2000-04-29 2016-07-25 Univ Iowa Res Found Diagnosis and treatment of macular degeneration-related disorders
US7560534B2 (en) 2000-05-08 2009-07-14 Celldex Research Corporation Molecular conjugates comprising human monoclonal antibodies to dendritic cells
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
AU2002239422B2 (en) 2000-11-30 2006-12-07 E. R. Squibb & Sons, L.L.C. Transgenic transchromosomal rodents for making human antibodies
PE20020574A1 (en) 2000-12-06 2002-07-02 Wyeth Corp HUMANIZED ANTIBODIES THAT RECOGNIZE THE AMYLOID PEPTIDE BETA
JP3986439B2 (en) 2001-02-07 2007-10-03 中外製薬株式会社 Hematopoietic tumor therapeutic agent
UA80091C2 (en) 2001-04-02 2007-08-27 Chugai Pharmaceutical Co Ltd Remedies for infant chronic arthritis-relating diseases and still's disease which contain an interleukin-6 (il-6) antagonist
CN1547486A (en) 2001-06-26 2004-11-17 Antibodies to OPGL
WO2003030831A2 (en) 2001-10-11 2003-04-17 Protein Design Labs, Inc. Treatment of prostate cancer by inhibitors of atp synthase
CA2468565C (en) 2001-11-30 2014-06-03 Abgenix, Inc. Transgenic animals bearing human iglambda light chain genes
US8840884B2 (en) 2002-02-14 2014-09-23 Chugai Seiyaku Kabushiki Kaisha Antibody-containing solution pharmaceuticals
CA2477249A1 (en) 2002-02-25 2003-09-04 Genentech, Inc. Novel type-1 cytokine receptor glm-r
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
EP2314316A1 (en) 2002-04-05 2011-04-27 Amgen, Inc Human anti-OPGL neutralizing antibodies as selective OPGL pathway inhibitors
CA2481207C (en) 2002-04-12 2015-06-30 Medarex, Inc. Methods of treatment using ctla-4 antibodies
EP1506002A4 (en) 2002-05-17 2006-06-07 Protein Design Labs Treatment of crohn's disease or psoriasis using anti-inteferon gamma antibodies
EP2316921B1 (en) 2002-05-24 2014-05-14 Merck Sharp & Dohme Corp. Neutralizing human anti-IGFR antibody
JP2005535636A (en) 2002-06-28 2005-11-24 アメリカ合衆国 Methods for treating autoimmune diseases using interferon beta and IL-2R antagonists
USRE47770E1 (en) 2002-07-18 2019-12-17 Merus N.V. Recombinant production of mixtures of antibodies
EP1541165A4 (en) 2002-08-27 2009-06-24 Chugai Pharmaceutical Co Ltd Method of stabilizing protein solution preparation
AU2002338020A1 (en) 2002-09-04 2004-03-29 Chugai Seiyaku Kabushiki Kaisha Antibody against blood-solubilized n-terminal peptide in gpc3
AR041173A1 (en) 2002-09-06 2005-05-04 Amgen Inc ANTI-IL- 1R1 MONOCLONAL ANTI-BODY THERAPEUTIC HUMAN
KR101119448B1 (en) 2002-09-11 2012-03-15 추가이 세이야쿠 가부시키가이샤 Method of purifying protein
WO2010011999A2 (en) 2008-07-25 2010-01-28 The Regents Of The University Of California Methods and compositions for eliciting an amyloid-selective immune response
TW200413725A (en) 2002-09-30 2004-08-01 Oncotherapy Science Inc Method for diagnosing non-small cell lung cancers
AU2003285874A1 (en) 2002-10-16 2004-05-04 Amgen Inc. HUMAN ANTI-IFN-Gamma NEUTRALIZING ANTIBODIES AS SELECTIVE IFN-Gamma PATHWAY INHIBITORS
RU2377253C2 (en) 2002-12-02 2009-12-27 Амген Фремонт,Инк. Antibodies specific to tumour necrosis factor, and application thereof
US9259459B2 (en) 2003-01-31 2016-02-16 Celldex Therapeutics Inc. Antibody vaccine conjugates and uses therefor
JP2006516637A (en) 2003-01-31 2006-07-06 セルデックス セラピューティクス， インク． Antibody vaccine conjugates and methods of use thereof
JP2007525434A (en) 2003-03-19 2007-09-06 アブジェニックス インコーポレイテッド Antibodies to T cells, immunoglobulin domain and mucin domain 1 (TIM-1) antigen and uses thereof.
US20040208876A1 (en) 2003-04-18 2004-10-21 Kim Kyung Jin Monoclonal antibodies to hepatocyte growth factor
GB2401040A (en) 2003-04-28 2004-11-03 Chugai Pharmaceutical Co Ltd Method for treating interleukin-6 related diseases
US7709610B2 (en) 2003-05-08 2010-05-04 Facet Biotech Corporation Therapeutic use of anti-CS1 antibodies
US20050025763A1 (en) 2003-05-08 2005-02-03 Protein Design Laboratories, Inc. Therapeutic use of anti-CS1 antibodies
US7358331B2 (en) 2003-05-19 2008-04-15 Elan Pharmaceuticals, Inc. Truncated fragments of alpha-synuclein in Lewy body disease
EP2395017A3 (en) 2003-05-30 2012-12-19 Merus B.V. Design and use of paired variable regions of specific binding molecules
US20100069614A1 (en) 2008-06-27 2010-03-18 Merus B.V. Antibody producing non-human mammals
US7405274B2 (en) 2003-06-04 2008-07-29 Fibrogen, Inc. Connective tissue growth factor antibodies
EP1635763B1 (en) 2003-06-09 2012-08-08 Alnylam Pharmaceuticals Inc. Method of treating neurodegenerative disease
ES2348008T3 (en) 2003-06-18 2010-11-26 Chugai Seiyaku Kabushiki Kaisha FUCOSA TRANSPORTER.
EP2457587A1 (en) 2003-06-27 2012-05-30 Amgen Fremont Inc. Anitbodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof
US8153410B2 (en) 2003-07-07 2012-04-10 Fox Chase Cancer Center Alternate morpheein forms of allosteric proteins as a target for the development of bioactive molecules
US20060162014A1 (en) 2003-07-07 2006-07-20 Jaffe Eileen K Alternate morpheeins of allosteric proteins as a target for the development of bioactive molecules
EP1648998B1 (en) 2003-07-18 2014-10-01 Amgen Inc. Specific binding agents to hepatocyte growth factor
US20080153104A1 (en) 2003-08-08 2008-06-26 Hiroyuki Aburantai Gene Overexpressed in Cancer
US7288253B2 (en) 2003-08-08 2007-10-30 Amgen Fremont, Inc. Antibodies directed to parathyroid hormone (PTH) and uses thereof
AU2003271174A1 (en) 2003-10-10 2005-04-27 Chugai Seiyaku Kabushiki Kaisha Double specific antibodies substituting for functional protein
JPWO2005035754A1 (en) 2003-10-14 2006-12-21 中外製薬株式会社 Bispecific antibodies that replace functional proteins
US8298816B2 (en) 2003-12-03 2012-10-30 Chugai Seiyaku Kabushiki Kaisha Expression systems using mammalian beta-actin promoter
DK2383295T3 (en) 2003-12-10 2015-06-15 Squibb & Sons Llc Ip-10 antibodies and uses thereof
EP2418220B1 (en) 2003-12-10 2017-08-02 E. R. Squibb & Sons, L.L.C. Interferon alpha antibodies and their uses
WO2005056605A1 (en) 2003-12-12 2005-06-23 Chugai Seiyaku Kabushiki Kaisha Modified antibodies recognizing trimer receptor or higher
WO2005092926A2 (en) 2004-03-19 2005-10-06 Amgen Inc. Reducing the risk of human and anti-human antibodies through v gene manipulation
US7625549B2 (en) 2004-03-19 2009-12-01 Amgen Fremont Inc. Determining the risk of human anti-human antibodies in transgenic mice
DE602005025998D1 (en) 2004-03-23 2011-03-03 Oncotherapy Science Inc METHOD FOR THE DIAGNOSIS OF NON-SMALL CELLULOSE CANCER
US20050227289A1 (en) 2004-04-09 2005-10-13 Reilly Edward B Antibodies to erythropoietin receptor and uses thereof
EP1781705B1 (en) 2004-06-21 2014-10-08 Medarex, L.L.C. Interferon alpha receptor i antibodies and their uses
AU2005259221B2 (en) 2004-07-01 2011-02-10 Innate Pharma Antibodies binding to receptors KIR2DL1, -2, 3 but not KIR2DS4 and their therapeutic use
US7973134B2 (en) 2004-07-07 2011-07-05 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in anaplastic large cell lymphoma signaling pathways
EP2216046B1 (en) 2004-07-09 2014-03-12 Chugai Seiyaku Kabushiki Kaisha Anti-glypican 3 antibody
ME00226B (en) 2004-07-15 2011-02-10 Medarex Llc Human anti-ngf neutralizing antibodies as selective ngf pathway inhibitors
US7935790B2 (en) 2004-10-04 2011-05-03 Cell Singaling Technology, Inc. Reagents for the detection of protein phosphorylation in T-cell receptor signaling pathways
CN101389214A (en) 2004-10-22 2009-03-18 雷维维科公司 Ungulates with genetically modified immune systems
US20080026457A1 (en) 2004-10-22 2008-01-31 Kevin Wells Ungulates with genetically modified immune systems
EP1812062B1 (en) 2004-10-25 2022-03-09 Merck Sharp & Dohme Corp. Anti-addl antibodies and uses thereof
AU2005307831A1 (en) 2004-11-17 2006-05-26 Amgen, Inc. Fully human monoclonal antibodies to IL-13
CA2590337C (en) 2004-12-15 2017-07-11 Neuralab Limited Humanized amyloid beta antibodies for use in improving cognition
US7572444B2 (en) 2004-12-20 2009-08-11 Amgen Fremont Inc. Binding proteins specific for human matriptase
US7807789B2 (en) 2004-12-21 2010-10-05 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in EGFR-signaling pathways
WO2006068953A2 (en) 2004-12-21 2006-06-29 Astrazeneca Ab Antibodies directed to angiopoietin-2 and uses thereof
JPWO2006067847A1 (en) 2004-12-22 2008-06-12 中外製薬株式会社 Antibody production method using cells in which fucose transporter function is inhibited
US7566772B2 (en) 2005-01-26 2009-07-28 Amgen Fremont Inc. Antibodies against interleukin-1β
WO2006104677A2 (en) 2005-03-24 2006-10-05 Millennium Pharmaceuticals, Inc. Antibodies that bind ov064 and methods of use therefor
CA2603408C (en) 2005-03-31 2018-08-21 Chugai Seiyaku Kabushiki Kaisha Methods for producing polypeptides by regulating polypeptide association
SI1876236T1 (en) 2005-04-08 2014-11-28 Chugai Seiyaku Kabushiki Kaisha Antibody substituting for function of blood coagulation factor viii
EP2161336B2 (en) 2005-05-09 2017-03-29 ONO Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
KR101367544B1 (en) 2005-06-10 2014-02-26 추가이 세이야쿠 가부시키가이샤 Stabilizer for protein preparation comprising meglumine and use thereof
PT1907424E (en) 2005-07-01 2015-10-09 Squibb & Sons Llc Human monoclonal antibodies to programmed death ligand 1 (pd-l1)
RS54984B1 (en) 2005-07-18 2016-11-30 Amgen Inc Human anti-b7rp1 neutralizing antibodies
NZ594784A (en) 2005-08-18 2013-06-28 Genmab As Therapy with CD4 binding peptides and radiation
EP1934867A2 (en) 2005-08-31 2008-06-25 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in leukemia signaling pathways
US8193328B2 (en) 2005-09-08 2012-06-05 Philadelphia Health & Education Corporation Identification of modulators of serine protease inhibitor Kazal and their use as anti-cancer and anti-viral agents
US8945573B2 (en) 2005-09-08 2015-02-03 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Targeted identification of immunogenic peptides
WO2007038637A2 (en) 2005-09-26 2007-04-05 Medarex, Inc. Human monoclonal antibodies to cd70
CA2625773C (en) 2005-10-14 2015-05-12 Fukuoka University Inhibition of interleukin-6 (il-6) receptor promotes pancreatic islet transplantation
GB0521139D0 (en) 2005-10-18 2005-11-23 Univ Sheffield Therapeutic agent
RU2450830C2 (en) 2005-10-21 2012-05-20 Чугаи Сейяку Кабусики Кайся Agent for cardiopathy
KR20130020850A (en) 2005-10-21 2013-02-28 노파르티스 아게 Human antibodies against il-13 and therapeutic uses
EP1957115B8 (en) 2005-11-10 2014-03-05 Celldex Therapeutics, Inc. Method of treating ovarian and renal cancer using antibodies against t cell immunoglobulin domain and mucin domain 1 (tim-1) antigen
US8128934B2 (en) 2005-11-14 2012-03-06 Ribomic, Inc. Method for treatment or prevention of disease associated with functional disorder of regulatory T cell
PE20070684A1 (en) 2005-11-14 2007-08-06 Amgen Inc RANKL-PTH / PTHrP ANTIBODY CHEMERICAL MOLECULES
AR057582A1 (en) 2005-11-15 2007-12-05 Nat Hospital Organization AGENTS TO DELETE INDUCTION OF CYTOTOXIC T LYMPHOCYTES
TW200803894A (en) 2005-11-25 2008-01-16 Univ Keio Prostate cancer therapeutic agents
WO2007062676A1 (en) 2005-12-01 2007-06-07 B.R.A.H.M.S. Aktiengesellschaft Methods for the diagnosis and treatment of critically ill patients with endothelin, endothelin agonists and adrenomedullin antagonists
NZ568016A (en) 2005-12-07 2011-12-22 Medarex Inc CTLA-4 antibody dosage escalation regimens
AU2006321554B2 (en) 2005-12-08 2012-08-02 E. R. Squibb & Sons, L.L.C. Human monoclonal antibodies to Fucosyl-GM1 and methods for using anti-Fucosyl-GM1
DOP2006000277A (en) 2005-12-12 2007-08-31 Bayer Pharmaceuticals Corp ANTI MN ANTIBODIES AND METHODS FOR USE
PT1979001E (en) 2005-12-13 2012-07-13 Medimmune Ltd Binding proteins specific for insulin-like growth factors and uses thereof
GB2433740A (en) 2005-12-23 2007-07-04 Rapid Biosensor Systems Ltd Detection of tuberculosis infection
US9084777B2 (en) 2005-12-28 2015-07-21 Chugai Seiyaku Kabushiki Kaisha Stabilized antibody-containing formulations
AR056857A1 (en) 2005-12-30 2007-10-24 U3 Pharma Ag DIRECTED ANTIBODIES TO HER-3 (RECEIVER OF THE HUMAN EPIDERMAL GROWTH FACTOR-3) AND ITS USES
EP2463305B1 (en) 2006-01-12 2016-05-11 Alexion Pharmaceuticals, Inc. Antibodies to OX-2/CD200 and uses thereof
EP1976883B1 (en) 2006-01-17 2012-10-03 Medarex, Inc. Monoclonal antibodies against cd30 lacking in fucosyl and xylosyl residues
US20120208824A1 (en) 2006-01-20 2012-08-16 Cell Signaling Technology, Inc. ROS Kinase in Lung Cancer
US8771686B2 (en) 2006-01-27 2014-07-08 Chugai Seiyaku Kabushiki Kaisha Methods for treating a disease involving choroidal neovascularization by administering an IL-6 receptor antibody
AU2007235496B2 (en) 2006-03-31 2013-11-21 E. R. Squibb & Sons, L.L.C. Transgenic animals expressing chimeric antibodies for use in preparing human antibodies
JP5624276B2 (en) 2006-03-31 2014-11-12 中外製薬株式会社 Methods for controlling blood kinetics of antibodies
CN105177091A (en) 2006-03-31 2015-12-23 中外制药株式会社 Antibody modification method for purifying bispecific antibody
AR059922A1 (en) 2006-04-01 2008-05-07 Galaxy Biotech Llc HUMANIZED MONOCLONAL ANTIBODIES FOR THE GROWTH FACTOR OF HEPATOCITS
KR20090029184A (en) 2006-04-07 2009-03-20 더 가브먼트 오브 더 유나이티드 스테이츠 오브 아메리카, 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 Antibody compositions and methods for treatment of neoplastic disease
CN106046166A (en) 2006-04-07 2016-10-26 爱尔皮奥治疗有限公司 Antibodies that bind to human protein tyrosine phosphatase [beta] (HPTP[beta]) and uses thereof
JP5754875B2 (en) 2006-04-07 2015-07-29 国立大学法人大阪大学 Muscle regeneration promoter
TW200813091A (en) 2006-04-10 2008-03-16 Amgen Fremont Inc Targeted binding agents directed to uPAR and uses thereof
WO2007119796A1 (en) 2006-04-14 2007-10-25 Medical And Biological Laboratories Co., Ltd. Mutant polypeptide having effector function
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
EP2011513B1 (en) 2006-04-25 2016-10-19 The University of Tokyo Therapeutic agents for alzheimer's disease and cancer
EP2035448A4 (en) 2006-06-01 2010-11-03 Elan Pharm Inc Neuroactive fragments of app
UA100116C2 (en) 2006-06-08 2012-11-26 Чугей Сейяку Кабусики Кайся Preventive or remedy for inflammatory disease
MX2008015975A (en) 2006-06-14 2009-03-26 Chugai Pharmaceutical Co Ltd Hematopoietic stem cell proliferation promoter.
AR061986A1 (en) 2006-07-13 2008-08-10 Chugai Pharmaceutical Co Ltd CELLULAR DEATH INDUCTIVE AGENTS
JP5175729B2 (en) 2006-07-21 2013-04-03 中外製薬株式会社 Kidney disease treatment
CL2007002225A1 (en) 2006-08-03 2008-04-18 Astrazeneca Ab SPECIFIC UNION AGENT FOR A RECEIVER OF THE GROWTH FACTOR DERIVED FROM PLATES (PDGFR-ALFA); NUCLEIC ACID MOLECULA THAT CODIFIES IT; VECTOR AND CELL GUESTS THAT UNDERSTAND IT; CONJUGADO UNDERSTANDING THE AGENT; AND USE OF THE AGENT OF A
CN101553505B (en) 2006-08-03 2013-07-17 阿斯利康(瑞典)有限公司 Antibodies directed to alphaVbeta6 and uses thereof
US7939636B2 (en) 2006-08-11 2011-05-10 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in c-Src signaling pathways
US20100092457A1 (en) 2006-08-14 2010-04-15 Forerunner Pharma Research Co., Ltd. Diagnosis and Treatment of Cancer Using Anti-Desmoglein-3 Antibodies
EA200970250A1 (en) 2006-09-05 2010-02-26 Медарекс, Инк. ANTIBODIES TO BONE MORPHOGENETIC PROTEINS AND THEIR RECEPTORS AND METHODS OF THEIR APPLICATION
EP2083017A4 (en) 2006-09-14 2011-01-12 Med & Biological Lab Co Ltd Antibody having enhanced adcc activity and method for production thereof
ES2553553T3 (en) 2006-10-02 2015-12-10 E. R. Squibb & Sons, L.L.C. Human antibodies that bind to CXCR4 and their uses
MY162056A (en) 2006-10-12 2017-05-31 Univ Tokyo Diagnosis and treatment of cancer using anti -ereg antibody
EP2068922B1 (en) 2006-10-19 2012-06-27 CSL Limited Anti-il-13r alpha 1 antibodies and their uses thereof
JP5378795B2 (en) 2006-10-20 2013-12-25 中外製薬株式会社 Pharmaceutical composition comprising anti-HB-EGF antibody as an active ingredient
US9023993B2 (en) 2006-10-20 2015-05-05 Chugai Seiyaku Kabushiki Kaisha Anti-cancer agent comprising anti-HB-EGF antibody as active ingredient
NZ577085A (en) 2006-11-15 2012-06-29 Medarex Inc Human monoclonal antibodies to btla and methods of use
US8481683B2 (en) 2006-12-01 2013-07-09 Medarex, Inc. Human antibodies that bind CD22 and uses thereof
CL2007003622A1 (en) 2006-12-13 2009-08-07 Medarex Inc Human anti-cd19 monoclonal antibody; composition comprising it; and tumor cell growth inhibition method.
CA2672581A1 (en) 2006-12-14 2008-06-19 Forerunner Pharma Research Co., Ltd. Anti-claudin 3 monoclonal antibody and treatment and diagnosis of cancer using the same
JP2010513306A (en) 2006-12-14 2010-04-30 メダレックス インコーポレーティッド Human antibodies that bind to CD70 and uses thereof
US20100111851A1 (en) 2007-01-05 2010-05-06 The University Of Tokyo Diagnosis and treatment of cancer by using anti-prg-3 antibody
ES2564392T3 (en) 2007-01-23 2016-03-22 Shinshu University IL-6 inhibitors for the treatment of chronic rejection
US20100216977A1 (en) 2007-02-15 2010-08-26 Kyushu University, National University Corporation Therapeutic agent for interstitial pulmonary disease comprising anti-hmgb-1 antibody
WO2008100624A2 (en) 2007-02-16 2008-08-21 Merrimack Pharmaceuticals, Inc. Antibodies against erbb3 and uses thereof
JP5374360B2 (en) 2007-02-27 2013-12-25 中外製薬株式会社 Pharmaceutical composition comprising anti-GRP78 antibody as an active ingredient
EP1972639A3 (en) 2007-03-07 2008-12-03 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in carcinoma signaling pathways
CL2008000719A1 (en) 2007-03-12 2008-09-05 Univ Tokushima Chugai Seiyaku THERAPEUTIC AGENT FOR CANCER RESISTANT TO CHEMOTHERAPEUTIC AGENTS THAT UNDERSTAND AN ANTIBODY THAT RECOGNIZES IT CLASS I AS ACTIVE INGREDIENT; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH ANTIBODY; AND METHOD TO TREAT CANCER RESISTANT TO
CN101679521B (en) 2007-03-22 2014-03-12 拜奥根Idec马萨诸塞公司 Binding proteins, including antibodies, antibody derivatives and antibody fragments, that specifically bind CD154 and uses thereof
US20090068684A1 (en) 2007-03-26 2009-03-12 Cell Signaling Technology, Inc. Serine and threoninephosphorylation sites
US8003097B2 (en) 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
EP1983003A3 (en) 2007-04-19 2009-03-11 Peter Hornbeck Tyrosine phosphorylation sites and antibodies specific for them
US7977462B2 (en) 2007-04-19 2011-07-12 Cell Signaling Technology, Inc. Tyrosine phosphorylation sites
EP1983002A3 (en) 2007-04-19 2009-03-11 Peter Hornbeck Tyrosine phosphorylation sites and antibodies specific for them
FI20075278A0 (en) 2007-04-20 2007-04-20 Biotie Therapies Corp Novel completely human anti-VAP-1 monoclonal antibodies
US20090053831A1 (en) 2007-05-01 2009-02-26 Cell Signaling Technology, Inc. Tyrosine phosphorylation sites
JP5117765B2 (en) 2007-05-28 2013-01-16 国立大学法人 東京大学 Tumor diagnostic agent for PET containing anti-ROBO1 antibody
US7709215B2 (en) 2007-06-01 2010-05-04 Cytonics Corporation Method for diagnosing and treating acute joint injury
CN103694351A (en) 2007-06-05 2014-04-02 耶鲁大学 Inhibitors of receptor tyrosine kinases and methods of use thereof
US20080317768A1 (en) 2007-06-21 2008-12-25 Boeing Company Bioconjugated nanoparticles
JP5469456B2 (en) 2007-06-25 2014-04-16 中外製薬株式会社 Anti-Prominin-1 antibody having ADCC activity or CDC activity
EP3246045A1 (en) 2007-07-26 2017-11-22 Osaka University Therapeutic agents for ocular inflammatory disease comprising interleukin 6 receptor inhibitor as active ingredient
ES2498040T3 (en) 2007-07-27 2014-09-24 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases with humanized anti-beta antibodies
CA2695237A1 (en) 2007-08-02 2009-04-30 Novimmune S.A. Anti-rantes antibodies and methods of use thereof
US9693539B2 (en) 2007-08-10 2017-07-04 E. R. Squibb & Sons, L.L.C. HCO32 and HCO27 and related examples
US8865875B2 (en) 2007-08-22 2014-10-21 Medarex, L.L.C. Site-specific attachment of drugs or other agents to engineered antibodies with C-terminal extensions
JOP20080381B1 (en) 2007-08-23 2023-03-28 Amgen Inc Antigen Binding Proteins to Proprotein Convertase subtillisin Kexin type 9 (pcsk9)
EP4248976A3 (en) 2007-08-23 2024-04-10 Amgen Inc. Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (pcsk9)
ES2537580T3 (en) 2007-09-04 2015-06-09 Compugen Ltd. Polypeptides and polynucleotides, and uses thereof as a pharmacological target to produce drugs and biological agents
TW200918553A (en) 2007-09-18 2009-05-01 Amgen Inc Human GM-CSF antigen binding proteins
PL2207809T3 (en) 2007-09-26 2014-02-28 U3 Pharma Gmbh Heparin-binding epidermal growth factor-like growth factor antigen binding proteins
HUE029635T2 (en) 2007-09-26 2017-03-28 Chugai Pharmaceutical Co Ltd Method of modifying isoelectric point of antibody via amino acid substitution in cdr
US8497355B2 (en) 2007-09-28 2013-07-30 Chugai Seiyaku Kabushiki Kaisha Anti-glypican-3 antibody having improved kinetics in plasma
KR101601986B1 (en) 2007-10-02 2016-03-17 추가이 세이야쿠 가부시키가이샤 Remedy for graft-versus-host disease comprising interleukin-6 receptor inhibitor as the active ingredient
TWI489993B (en) 2007-10-12 2015-07-01 Novartis Ag Compositions and methods of use for antibodies against sclerostin
WO2009051108A1 (en) 2007-10-15 2009-04-23 Chugai Seiyaku Kabushiki Kaisha Method for production of antibody
JO3076B1 (en) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap Immunotherapy regimes dependent on apoe status
DK2203558T3 (en) 2007-10-18 2016-06-27 Cell Signaling Technology Inc TRANSLOCATION AND mutant ROS kinase IN HUMAN NON-small cell lung carcinoma
EP2230300A4 (en) 2007-10-24 2012-08-08 Otsuka Chemical Holdings Co Ltd Polypeptide having enhanced effector function
US20100254980A1 (en) 2007-11-02 2010-10-07 Novartis Ag Molecules and methods for modulating low-density-lipoprotein receptor-related protein 6 (lrp6)
SG187482A1 (en) 2007-11-07 2013-02-28 Celldex Therapeutics Inc Antibodies that bind human dendritic and epithelial cell 205 (dec-205)
CN103275227B (en) 2007-11-12 2015-02-11 U3制药有限公司 AXL antibodies
CN104109208A (en) 2007-11-14 2014-10-22 中外制药株式会社 Diagnosis And Treatment Of Cancer Using Anti-gpr49 Antibody
AR069333A1 (en) 2007-11-15 2010-01-13 Chugai Pharmaceutical Co Ltd MONOCLONAL ANTIBODIES THAT JOIN THE TIROSIN QUINASA ANEXELEKTO (AXL) RECEIVER, HYBRIDOMES THAT PRODUCE THEM AND THEIR USES
EP2062920A3 (en) 2007-11-21 2009-06-17 Peter Hornbeck Protein phosphorylation by basophilic serine/threonine kinases in insulin signalling pathways
AU2008332276B2 (en) 2007-12-05 2014-02-27 Chugai Seiyaku Kabushiki Kaisha Therapeutic agent for pruritus
US20110129459A1 (en) 2007-12-05 2011-06-02 Chugai Seiyaku Kabushiki Kaisha Anti-nr10 antibody and use thereof
JPWO2009075344A1 (en) 2007-12-12 2011-04-28 独立行政法人国立がん研究センター MLL leukemia and MOZ leukemia therapeutic agent using M-CSF receptor as molecular target, and use thereof
PL2222706T5 (en) 2007-12-14 2017-09-29 Novo Nordisk As Antibodies against human nkg2d and uses thereof
US8779088B2 (en) 2007-12-17 2014-07-15 Marfl Ab Vaccine for the treatment of Mycobacterium related disorders
PE20091174A1 (en) 2007-12-27 2009-08-03 Chugai Pharmaceutical Co Ltd LIQUID FORMULATION WITH HIGH CONCENTRATION OF ANTIBODY CONTENT
PL2237803T3 (en) 2007-12-28 2015-12-31 Prothena Therapeutics Ltd Treatment and prophylaxis of amyloidosis
EP3064512B1 (en) 2008-01-11 2023-08-30 The University of Tokyo Anti-cldn6 antibody
FR2926438B1 (en) * 2008-01-22 2013-01-11 Univ Limoges NON-HUMAN TRANSGENIC MAMMAL FOR THE CONSTANT REGION OF THE HEAVY CHAIN OF HUMAN CLASS G IMMUNOGLOBULINS AND ITS APPLICATIONS
EP2240203B1 (en) 2008-02-05 2014-04-09 Bristol-Myers Squibb Company Alpha 5 - beta 1 antibodies and their uses
CL2009000647A1 (en) 2008-04-04 2010-06-04 Chugai Pharmaceutical Co Ltd Pharmaceutical composition for treating or preventing liver cancer comprising a combination of a chemotherapeutic agent and an anti-glypican 3 antibody; agent for attenuating a side effect comprising said antibody; method of treating or preventing liver cancer of a subject.
WO2009126306A2 (en) 2008-04-10 2009-10-15 Cell Signaling Technology, Inc. Compositions and methods for detecting egfr mutations in cancer
TW202423982A (en) 2008-04-11 2024-06-16 日商中外製藥股份有限公司 Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
BRPI0912035A2 (en) 2008-05-29 2017-05-23 Galaxy Biotech Llc monoclonal antibody, pharmaceutical composition, use of a pharmaceutical composition, mouse mab in chimeric or humanized form, and humanized antibody
US9226934B2 (en) 2008-06-02 2016-01-05 The University Of Tokyo Anti-cancer drug
WO2009148148A1 (en) 2008-06-05 2009-12-10 国立がんセンター総長が代表する日本国 Neuroinvasion inhibitor
CN102124030B (en) 2008-06-20 2015-06-17 国立大学法人冈山大学 Antibody against oxidized ldl/ss2gpi complex and use of the same
DK2147594T3 (en) * 2008-06-27 2014-02-10 Merus B V Antibody-producing non-human mammals
SG10201405377XA (en) 2008-08-05 2014-12-30 Novartis Ag Compositions and methods for antibodies targeting complement protein c5
AR072999A1 (en) 2008-08-11 2010-10-06 Medarex Inc HUMAN ANTIBODIES THAT JOIN GEN 3 OF LYMPHOCYTARY ACTIVATION (LAG-3) AND THE USES OF THESE
EP2344536A1 (en) 2008-09-19 2011-07-20 MedImmune, LLC Antibodies directed to dll4 and uses thereof
DK2346994T3 (en) 2008-09-30 2022-02-28 Ablexis Llc Knock-in mice for the production of chimeric antibodies
DK2348827T3 (en) 2008-10-27 2015-07-20 Revivicor Inc IMMUNICIPLY COMPROMATED PETS
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
LT3290052T (en) 2008-11-07 2020-02-25 Galaxy Biotech, Llc Monoclonal antibodies to fibroblast growth factor receptor 2
LT2894165T (en) 2008-11-10 2023-03-10 Alexion Pharmaceuticals, Inc. Methods and compositions for treating complement-associated disorders
CN102300874B (en) 2008-12-08 2015-08-05 卡姆普根有限公司 TMEM154 polypeptide and polynucleotide and as the purposes of drug targets producing medicine and biological products
UA109633C2 (en) 2008-12-09 2015-09-25 HUMAN ANTIBODY AGAINST TISSUE FACTOR
CN102292445A (en) * 2008-12-18 2011-12-21 伊拉兹马斯大学鹿特丹医学中心 Non-human transgenic animals expressing humanized antibodies and uses thereof
WO2010074049A1 (en) 2008-12-22 2010-07-01 株式会社 未来創薬研究所 Anti-hs6st2 antibody and use thereof
CA2748158A1 (en) 2008-12-23 2010-07-01 Astrazeneca Ab Targeted binding agents directed to .alpha.5.beta.1 and uses thereof
EP2385114A4 (en) 2008-12-25 2012-08-08 Univ Tokyo Diagnosis of treatment of cancer using anti-tm4sf20 antibody
CA2748990A1 (en) 2008-12-26 2010-07-01 The University Of Tokyo Diagnosis and treatment of cancer using anti-lgr7 antibody
WO2010085590A1 (en) 2009-01-23 2010-07-29 Biosynexus Incorporated Opsonic and protective antibodies specific for lipoteichoic acid gram positive bacteria
EP2881402B1 (en) 2009-02-12 2017-05-10 Cell Signaling Technology, Inc. Mutant ROS expression in human liver cancer
US8420084B2 (en) 2009-03-05 2013-04-16 Medarex, Inc. Fully human antibodies specific to CADM1
JP2010210772A (en) 2009-03-13 2010-09-24 Dainippon Screen Mfg Co Ltd Method of manufacturing liquid crystal display device
AU2010235238B2 (en) 2009-04-08 2015-01-29 Lipum Ab New methods for treatment of inflammatory diseases
EP2420515A4 (en) 2009-04-16 2013-08-28 Univ Tokyo Diagnosis and treatment of cancer using anti-tmprss11e antibody
WO2010119991A2 (en) 2009-04-17 2010-10-21 Takeda Pharmaceutical Company Limited Novel method of treating cancer
WO2010124113A1 (en) 2009-04-23 2010-10-28 Infinity Pharmaceuticals, Inc. Anti-fatty acid amide hydrolase-2 antibodies and uses thereof
EA027071B1 (en) 2009-04-27 2017-06-30 Новартис Аг ANTI-ActRIIB ANTIBODY AND COMPOSITION COMPRISING SAME
JP2012524524A (en) 2009-04-27 2012-10-18 ノバルティス アーゲー Composition of therapeutic antibodies specific for IL-12 receptor β1 subunit and methods of use
WO2010126137A1 (en) 2009-05-01 2010-11-04 国立大学法人 東京大学 Anti-cadherin antibody
DK2448970T3 (en) 2009-05-04 2014-10-06 Abbvie Res B V ANTIBODIES AGAINST NERVOUS GROWTH FACTOR (NGF) WITH IMPROVED IN VIVO STABILITY
KR101811886B1 (en) 2009-05-05 2017-12-22 노비뮨 에스 에이 Anti-IL-17F Antibodies and Methods of Use Thereof
EP2436397B1 (en) 2009-05-29 2017-05-10 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical composition containing antagonist of egf family ligand as component
WO2010151632A1 (en) 2009-06-25 2010-12-29 Bristol-Myers Squibb Company Protein purifacation by caprylic acid (octanoic acid ) precipitation
PL3241435T3 (en) 2009-07-08 2021-12-13 Kymab Limited Animal models and therapeutic molecules
US9445581B2 (en) 2012-03-28 2016-09-20 Kymab Limited Animal models and therapeutic molecules
CA2768247C (en) 2009-07-17 2019-04-09 Bioatla, Llc Simultaneous, integrated selection and evolution of antibody/protein performance and expression in production hosts
TWI523661B (en) 2009-07-31 2016-03-01 Shin Maeda Anti-IL-6 receptor antibody in the manufacture of inhibitors of metastatic inhibition of lung cancer metastasis to the liver
SG177689A1 (en) 2009-07-31 2012-02-28 Organon Nv Fully human antibodies to btla
WO2011017294A1 (en) 2009-08-07 2011-02-10 Schering Corporation Human anti-rankl antibodies
WO2011021381A1 (en) 2009-08-17 2011-02-24 株式会社未来創薬研究所 Pharmaceutical composition containing anti-hb-egf antibody as active ingredient
WO2011021146A1 (en) 2009-08-20 2011-02-24 Pfizer Inc. Osteopontin antibodies
US20120178910A1 (en) 2009-09-23 2012-07-12 Medarex, Inc. Cation exchange chromatography (methods)
TW201118166A (en) 2009-09-24 2011-06-01 Chugai Pharmaceutical Co Ltd HLA class I-recognizing antibodies
KR101640520B1 (en) 2009-10-16 2016-07-19 르 라보레또레 쎄르비에르 Monoclonal antibodies to progastrin and their uses
PL2490720T3 (en) 2009-10-23 2020-08-24 Millennium Pharmaceuticals, Inc. Anti-gcc antibody molecules and related compositions and methods
EP2496604B1 (en) 2009-11-06 2017-08-23 IDEXX Laboratories, Inc. Canine anti-cd20 antibodies
IN2012DN04412A (en) 2009-11-09 2015-08-07 Alexion Pharmaceuticals Inc
PT3351558T (en) 2009-11-13 2020-04-09 Daiichi Sankyo Europe Gmbh Material and methods for treating or preventing her-3 associated diseases
NO2501822T3 (en) 2009-11-17 2018-01-13
KR101740171B1 (en) 2009-11-24 2017-05-25 메디뮨 리미티드 Targeted binding agents against b7-h1
US9428586B2 (en) 2009-12-01 2016-08-30 Compugen Ltd Heparanase splice variant
US8765432B2 (en) 2009-12-18 2014-07-01 Oligasis, Llc Targeted drug phosphorylcholine polymer conjugates
WO2011085343A1 (en) 2010-01-11 2011-07-14 Alexion Pharmaceuticals, Inc Biomarkers of immunomodulatory effects in humans treated with anti-cd200 antibodies
TWI505838B (en) 2010-01-20 2015-11-01 Chugai Pharmaceutical Co Ltd Stabilized antibody
WO2011092989A1 (en) 2010-01-29 2011-08-04 東レ株式会社 Polylactic acid-based resin sheet
TR201806936T4 (en) 2010-01-29 2018-06-21 Chugai Pharmaceutical Co Ltd Anti-dll3 antibody.
WO2011097511A1 (en) 2010-02-05 2011-08-11 The United States Of America, As Represented By The Secretary Department Of Health & Human Services REGULATORY B CELLS (tBREGS) AND THEIR USE
JP5380553B2 (en) 2010-02-10 2014-01-08 富士フイルムＲｉファーマ株式会社 Radioactive metal-labeled anti-cadherin antibody
JP2013520173A (en) 2010-02-18 2013-06-06 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Integrin αvβ8 neutralizing antibody
EP2540827A4 (en) 2010-02-26 2013-09-04 Chugai Pharmaceutical Co Ltd Anti-icam3 antibody and use thereof
WO2011109398A2 (en) 2010-03-02 2011-09-09 President And Fellows Of Harvard College Methods and compositions for treatment of angelman syndrome and autism spectrum disorders
EP2543730B1 (en) 2010-03-04 2018-10-31 Chugai Seiyaku Kabushiki Kaisha Antibody constant region variant
CN102892430A (en) 2010-03-17 2013-01-23 雅培研究有限公司 Anti-nerve growth factor (ngf) antibody compositions
US10745467B2 (en) 2010-03-26 2020-08-18 The Trustees Of Dartmouth College VISTA-Ig for treatment of autoimmune, allergic and inflammatory disorders
EP3153521B1 (en) 2010-03-26 2019-09-04 Trustees of Dartmouth College Vista regulatory t cell mediator protein, vista binding agents and use thereof
US20150231215A1 (en) 2012-06-22 2015-08-20 Randolph J. Noelle VISTA Antagonist and Methods of Use
TWI667346B (en) 2010-03-30 2019-08-01 中外製藥股份有限公司 Antibodies with modified affinity to fcrn that promote antigen clearance
KR102203727B1 (en) 2010-03-31 2021-01-18 아블렉시스, 엘엘씨 Genetic engineering of non-human animals for the production of chimeric antibodies
EA024701B1 (en) 2010-04-13 2016-10-31 Селлдекс Терапьютикс Инк. Antibodies that bind human cd27 and uses thereof
PL2563813T3 (en) 2010-04-30 2016-01-29 Alexion Pharma Inc Anti-c5a antibodies and methods for using the antibodies
WO2011140151A1 (en) 2010-05-04 2011-11-10 Dyax Corp. Antibodies against epidermal growth factor receptor (egfr)
US9044460B2 (en) 2010-05-04 2015-06-02 Merrimack Pharmaceuticals, Inc. Antibodies against epidermal growth factor receptor (EGFR) and uses thereof
SG185415A1 (en) 2010-05-06 2012-12-28 Novartis Ag Compositions and methods of use for therapeutic low density lipoprotein - related protein 6 (lrp6) multivalent antibodies
KR20130066632A (en) 2010-05-06 2013-06-20 노파르티스 아게 Compositions and methods of use for therapeutic low density lipoprotein-related protein 6 (lrp6) antibodies
US20130149302A1 (en) 2010-05-28 2013-06-13 Chugai Seiyaku Kabushiki Kaisha Therapeutic agents for pancreatic cancer
SI2578231T1 (en) 2010-05-28 2023-01-31 Chugai Seiyaku Kabushiki Kaisha Antitumor t cell response enhancer
LT2580243T (en) 2010-06-09 2020-01-27 Genmab A/S Antibodies against human cd38
KR101935058B1 (en) 2010-06-15 2019-01-03 젠맵 에이/에스 Human antibody drug conjugates against tissue factor
CA2803391C (en) 2010-06-22 2021-11-09 Neogenix Oncology, Inc. Npc1 antibodies that bind a muc5ac epitope
CA2803588A1 (en) 2010-06-22 2011-12-29 The Regents Of The University Of Colorado, A Body Corporate Antibodies to the c3d fragment of complement component 3
US20130315895A1 (en) 2010-07-01 2013-11-28 Takeda Pharmaceutical Company Limited COMBINATION OF A cMET INHIBITOR AND AN ANTIBODY TO HGF AND/OR cMET
WO2012009442A2 (en) 2010-07-14 2012-01-19 Merck Sharp & Dohme Corp. Anti-addl monoclonal antibody and uses thereof
EP2593797B1 (en) 2010-07-16 2019-05-08 Bioatla, LLC Novel methods of protein evolution
AU2011286407A1 (en) 2010-08-06 2013-02-21 Amgen Use of HER3 binding agents in prostate treatment
WO2012019132A2 (en) 2010-08-06 2012-02-09 Cell Signaling Technology, Inc. Anaplastic lymphoma kinase in kidney cancer
US20130253035A1 (en) 2010-08-16 2013-09-26 Duke University Camkk-beta as a target for treating cancer
UA114883C2 (en) 2010-08-20 2017-08-28 Новартіс Аг Antibodies for epidermal growth factor receptor 3 (her3)
AR083034A1 (en) 2010-09-17 2013-01-30 Baxter Int STABILIZATION OF IMMUNOGLOBULINS AND OTHER PROTEINS THROUGH A WATERY FORMULATION WITH SODIUM CHLORIDE AT A WEAK ACID pH NEUTRAL
US8999335B2 (en) 2010-09-17 2015-04-07 Compugen Ltd. Compositions and methods for treatment of drug resistant multiple myeloma
EP2433644A1 (en) 2010-09-22 2012-03-28 IMBA-Institut für Molekulare Biotechnologie GmbH Breast cancer therapeutics
EP2434285A1 (en) 2010-09-22 2012-03-28 IMBA-Institut für Molekulare Biotechnologie GmbH Breast cancer diagnostics
ES2719624T3 (en) 2010-09-23 2019-07-11 Prec Biologics Inc Peptidomimetics of colon and pancreas cancer
WO2012045703A1 (en) 2010-10-05 2012-04-12 Novartis Ag Anti-il12rbeta1 antibodies and their use in treating autoimmune and inflammatory disorders
BR112013008765B8 (en) * 2010-10-11 2023-05-02 Biogen Idec Int Neuroscience Gmbh ISOLATED MONOCLONAL ANTI-HUMAN TAU ANTIBODIES OR A TAU-BINDING FRAGMENT THEREOF, METHODS OF PREPARATION THEREOF, POLYNUCLEOTIDE OR POLYNUCLEOTIDES, VECTOR OR VECTORS, COMPOSITION, IN VITRO METHOD OF DIAGNOSIS OR MONITORING THE PROGRESSION OF A NEURODEHUMANIVATIVE TAUOPATHY , IN VITRO METHOD TO DIAGNOSE A NEURODEGENERATIVE TAUOPATHY IN A HUMAN INDIVIDUAL, AND USEFUL KIT FOR THE DIAGNOSIS OF A NEURODEGENERATIVE TAUOPATHY
KR20140014077A (en) 2010-10-25 2014-02-05 리전츠 오브 더 유니버스티 오브 미네소타 Therapeutic composition for treatment of glioblastoma
WO2012057328A1 (en) 2010-10-29 2012-05-03 株式会社ペルセウスプロテオミクス Anti-cdh3 antibody having high internalizing capability
NO2644698T3 (en) 2010-11-17 2018-06-02
GB201019467D0 (en) 2010-11-17 2010-12-29 Biotecnol Sa Therapeutic agent
US20130245233A1 (en) 2010-11-24 2013-09-19 Ming Lei Multispecific Molecules
KR102568454B1 (en) 2010-11-30 2023-08-18 추가이 세이야쿠 가부시키가이샤 Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly
EP4279512A3 (en) 2010-11-30 2024-02-28 Chugai Seiyaku Kabushiki Kaisha Cytotoxicity-inducing therapeutic agent
PL3156420T3 (en) 2010-12-06 2019-08-30 Seattle Genetics, Inc. Humanized antibodies to liv-1 and use of same to treat cancer
CN105924519B (en) 2010-12-31 2019-08-23 生物蛋白有限公司 Comprehensive monoclonal antibody generates
EP2668207A4 (en) 2011-01-24 2015-06-10 Univ Singapore Pathogenic mycobacteria-derived mannose-capped lipoarabinomannan antigen binding proteins
AR085141A1 (en) 2011-02-03 2013-09-11 Alexion Pharma Inc A METHOD FOR EXTENDING THE SURVIVAL OF A RENAL PAD, USE OF AN ANTIBODY ANTI-CD200 TO EXTEND THE SURVIVAL OF PADS
BR112013021526B1 (en) 2011-02-25 2021-09-21 Chugai Seiyaku Kabushiki Kaisha VARIANT POLYPEPTIDE, METHODS FOR MAINTAINING OR DECREASE BINDING ACTIVITIES TO FCGRIIA (TYPE R) AND FCGRIIA (TYPE H) AND INCREASING FCGRIIB BINDING ACTIVITY OF A POLYPEPTIDE AND FOR SUPPRESSING THE PRODUCTION OF AN ANTIBODY AGAINST A POLYENDENDOPEPTIDE ANTIBODY FC, METHODS FOR THE PRODUCTION OF SUCH POLYPEPTIDE WITH MAINTAINED OR DECREASED AND INCREASED BINDING ACTIVITIES AND FOR THE SUPPRESSED PRODUCTION OF AN ANTIBODY, PHARMACEUTICAL COMPOSITION AND USE OF A POLYPEPTIDE
EP2683736B1 (en) 2011-03-09 2018-01-17 Cell Signaling Technology, Inc. Methods and reagents for creating monoclonal antibodies
EP2500073A1 (en) 2011-03-17 2012-09-19 ChromaCon AG Method for identification and purification of multi-specific polypeptides
AU2012233313C1 (en) 2011-03-30 2017-08-03 Chugai Seiyaku Kabushiki Kaisha Method for altering plasma retention and immunogenicity of antigen-binding molecule
KR20140027211A (en) 2011-04-04 2014-03-06 유니버시티 오브 아이오와 리써치 파운데이션 Methods of improving vaccine immunogenicity
KR102001686B1 (en) 2011-04-07 2019-07-18 암젠 인크 Novel egfr binding proteins
WO2012142164A1 (en) 2011-04-12 2012-10-18 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Human monoclonal antibodies that bind insulin-like growth factor (igf) i and ii
US10232039B2 (en) 2011-04-12 2019-03-19 Duke University Compositions and methods for the treatment of tissue fibrosis
KR20140029446A (en) 2011-04-15 2014-03-10 컴퓨젠 엘티디. Polypeptides and polynucleotides, and uses thereof for treatment of immune related disorders and cancer
JP6104794B2 (en) 2011-04-18 2017-03-29 国立大学法人 東京大学 Diagnosis and treatment of cancer using anti-ITM2A antibody
JOP20200043A1 (en) 2011-05-10 2017-06-16 Amgen Inc Methods of treating or preventing cholesterol related disorders
CN107936121B (en) 2011-05-16 2022-01-14 埃泰美德(香港)有限公司 Multispecific FAB fusion proteins and methods of use thereof
TWI560200B (en) 2011-05-25 2016-12-01 Innate Pharma Sa Anti-kir antibodies for the treatment of inflammatory and autoimmune disorders
US8691231B2 (en) 2011-06-03 2014-04-08 Merrimack Pharmaceuticals, Inc. Methods of treatment of tumors expressing predominantly high affinity EGFR ligands or tumors expressing predominantly low affinity EGFR ligands with monoclonal and oligoclonal anti-EGFR antibodies
WO2012172495A1 (en) 2011-06-14 2012-12-20 Novartis Ag Compositions and methods for antibodies targeting tem8
EP2720721B1 (en) 2011-06-17 2017-08-30 President and Fellows of Harvard College Frizzled 2 as a target for therapeutic antibodies in the treatment of cancer
WO2013001517A1 (en) 2011-06-30 2013-01-03 Compugen Ltd. Polypeptides and uses thereof for treatment of autoimmune disorders and infection
BR112013032630B1 (en) 2011-06-30 2022-06-14 Chugai Seiyaku Kabushiki Kaisha HETERODIMERIZED POLYPEPTIDE COMPRISING IGG FC REGION
JP6472999B2 (en) 2011-07-01 2019-02-20 ノバルティス アーゲー Methods for treating metabolic disorders
WO2013010955A1 (en) 2011-07-15 2013-01-24 Morphosys Ag Antibodies that are cross-reactive for macrophage migration inhibitory factor (mif) and d-dopachrome tautomerase (d-dt)
EP2734546A1 (en) 2011-07-18 2014-05-28 Amgen Inc. Apelin antigen-binding proteins and uses thereof
WO2013012022A1 (en) 2011-07-19 2013-01-24 中外製薬株式会社 Stable protein-containing preparation containing argininamide or analogous compound thereof
WO2013017656A1 (en) 2011-08-02 2013-02-07 Medizinische Universität Wien Antagonists of ribonucleases for treating obesity
WO2013017691A1 (en) 2011-08-04 2013-02-07 Medizinische Universität Innsbruck Cahgt1p inhibitors for use in the treatment of candidiasis
EP2749572A4 (en) 2011-08-23 2015-04-01 Chugai Pharmaceutical Co Ltd Novel anti-ddr1 antibody having anti-tumor activity
EP2749641B1 (en) 2011-09-07 2021-06-02 Chugai Seiyaku Kabushiki Kaisha Cancer stem cell isolation
EP3128009B1 (en) * 2011-09-19 2020-07-29 Kymab Limited Antibodies, variable domains & chains tailored for human use
WO2013045916A1 (en) 2011-09-26 2013-04-04 Kymab Limited Chimaeric surrogate light chains (slc) comprising human vpreb
CA2791109C (en) 2011-09-26 2021-02-16 Merus B.V. Generation of binding molecules
KR20230066646A (en) 2011-09-30 2023-05-16 추가이 세이야쿠 가부시키가이샤 Antigen-binding molecule for promoting elimination of antigens
CN107287660A (en) 2011-09-30 2017-10-24 中外制药株式会社 Ion concentration dependence binding molecule library
EP2762493B1 (en) 2011-09-30 2021-06-09 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule promoting disappearance of antigens having plurality of biological activities
TW201817744A (en) 2011-09-30 2018-05-16 日商中外製藥股份有限公司 Therapeutic antigen-binding molecule with a FcRn-binding domain that promotes antigen clearance
US10556949B2 (en) 2011-09-30 2020-02-11 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule inducing immune response to target antigen
EP2765192A4 (en) 2011-10-05 2015-04-15 Chugai Pharmaceutical Co Ltd Antigen-binding molecule for promoting clearance from plasma of antigen comprising saccharide chain receptor-binding domain
CN104039351A (en) 2011-10-13 2014-09-10 阿尔皮奥治疗学股份有限公司 Methods for treating vascular leak syndrome and cancer
JP2014532072A (en) 2011-10-13 2014-12-04 エアピオ セラピューティックス， インコーポレイテッド Treatment of eye diseases
US9296826B2 (en) 2011-10-14 2016-03-29 Novartis Ag Antibodies and methods for WNT pathway-related diseases
CA2853822A1 (en) 2011-10-28 2013-05-02 Millennium Pharmaceuticals, Inc. Biomarkers of response to nae inhibitors
US20140302511A1 (en) 2011-10-28 2014-10-09 Pharmalogicals Research Pte. Ltd. Cancer stem cell-specific molecule
CA2853230C (en) 2011-10-31 2021-11-23 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule having regulated conjugation between heavy-chain and light-chain
AU2012332590B2 (en) 2011-11-01 2016-10-20 Bionomics, Inc. Anti-GPR49 antibodies
US10598653B2 (en) 2011-11-01 2020-03-24 Bionomics Inc. Methods of blocking cancer stem cell growth
EP2773665A1 (en) 2011-11-01 2014-09-10 Bionomics, Inc. Antibodies and methods of treating cancer
EP2773667A1 (en) 2011-11-01 2014-09-10 Bionomics, Inc. Anti-gpr49 antibodies
CN104039328B (en) 2011-11-11 2018-10-09 米伦纽姆医药公司 To the biomarker of the reaction of proteasome inhibitor
WO2013071163A2 (en) 2011-11-11 2013-05-16 Millennium Pharamaceuticals, Inc. Biomarkers of response to proteasome inhibitors
KR102176469B1 (en) 2011-11-16 2020-11-10 아드레노메드 아게 Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or an anti-adm non-ig scaffold for use in therapy
SG10201801919QA (en) 2011-11-16 2018-04-27 Adrenomed Ag Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for prevention or reduction of organ dysfunction or organ failure in a patient having a chronic or acute disease or acute condition
CA2856136A1 (en) 2011-11-16 2013-05-23 Adrenomed Ag Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for reducing the risk of mortality in a patient having a chronic or acute disease or acute condition
SG10201802054TA (en) 2011-11-16 2018-05-30 Adrenomed Ag Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for regulating the fluid balance in a patient having a chronic or acute disease
EA201490974A1 (en) 2011-11-16 2014-09-30 Эмджен Инк. METHODS OF TREATMENT OF DISORDERS ASSOCIATED WITH DELIVERY MUTANT VIII EPIDERMAL GROWTH FACTOR
US9140696B2 (en) 2011-11-16 2015-09-22 Adrenomed Ag Anti-adrenomedullin (ADM) antibody or anti-ADM antibody fragment or anti-ADM non-IG scaffold for reducing the risk of mortality in a patient having a chronic or acute disease or acute condition
SG11201402358RA (en) 2011-11-16 2014-06-27 Adrenomed Ag Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in therapy of an acute disease or acute condition of a patient for stabilizing the circulation
KR20210074395A (en) 2011-11-30 2021-06-21 추가이 세이야쿠 가부시키가이샤 Drug containing carrier into cell for forming immune complex
US9253965B2 (en) 2012-03-28 2016-02-09 Kymab Limited Animal models and therapeutic molecules
SG11201402739YA (en) 2011-12-05 2014-06-27 Novartis Ag Antibodies for epidermal growth factor receptor 3 (her3) directed to domain ii of her3
US9192663B2 (en) 2011-12-05 2015-11-24 Novartis Ag Antibodies for epidermal growth factor receptor 3 (HER3)
KR101924805B1 (en) * 2011-12-20 2018-12-04 리제너론 파마슈티칼스 인코포레이티드 Humanized light chain mice
BR112014015111A2 (en) 2011-12-21 2017-06-13 Novartis Ag p-factor targeting antibody compositions and processes
TWI593705B (en) 2011-12-28 2017-08-01 Chugai Pharmaceutical Co Ltd Humanized anti-epiregulin antibody and cancer therapeutic agent containing the antibody as an active ingredient
SG2014008304A (en) 2012-02-01 2014-06-27 Compugen Ltd C10rf32 antibodies, and uses thereof for treatment of cancer
NZ628314A (en) 2012-02-06 2017-01-27 Inhibrx Lp Cd47 antibodies and methods of use thereof
CN104204204A (en) 2012-02-09 2014-12-10 中外制药株式会社 Modified Fc region of antibody
TWI682939B (en) 2012-02-24 2020-01-21 日商中外製藥股份有限公司 Antigen-binding molecule that promotes antigen disappearance via FcγRIIB
US10251377B2 (en) 2012-03-28 2019-04-09 Kymab Limited Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies
GB2502127A (en) 2012-05-17 2013-11-20 Kymab Ltd Multivalent antibodies and in vivo methods for their production
US9751942B2 (en) 2012-03-29 2017-09-05 Chugai Seiyaku Kabushiki Kaisha Anti-LAMP5 antibody and utilization thereof
WO2013150623A1 (en) 2012-04-04 2013-10-10 株式会社ペルセウスプロテオミクス Conjugate of anti-cdh3 (p-cadherin) antibody and drug
EP3336181B1 (en) 2012-04-18 2022-01-12 Cell Signaling Technology, Inc. Egfr and ros1 in cancer
NZ799532A (en) 2012-04-20 2023-07-28 Merus Nv Methods and means for the production of ig-like molecules
EA039663B1 (en) 2012-05-03 2022-02-24 Амген Инк. Use of an anti-pcsk9 antibody for lowering serum cholesterol ldl and treating cholesterol related disorders
JP6267689B2 (en) 2012-05-10 2018-01-24 バイオアトラ、エルエルシー Multispecific monoclonal antibody
US20130309223A1 (en) 2012-05-18 2013-11-21 Seattle Genetics, Inc. CD33 Antibodies And Use Of Same To Treat Cancer
TWI617578B (en) 2012-05-30 2018-03-11 Chugai Pharmaceutical Co Ltd Target tissue-specific antigen binding molecule
WO2013180201A1 (en) 2012-05-30 2013-12-05 中外製薬株式会社 Antigen-binding molecule for eliminating aggregated antigens
WO2013188448A2 (en) 2012-06-11 2013-12-19 Amgen Inc. Dual receptor antagonistic antigen-binding proteins and uses thereof
US11142563B2 (en) 2012-06-14 2021-10-12 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule containing modified Fc region
WO2013192504A1 (en) 2012-06-22 2013-12-27 The Trustees Of Dartmouth College Novel vista-ig constructs and the use of vista-ig for treatment of autoimmune, allergic and inflammatory disorders
US9890215B2 (en) 2012-06-22 2018-02-13 King's College London Vista modulators for diagnosis and treatment of cancer
UY34887A (en) 2012-07-02 2013-12-31 Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware OPTIMIZATION OF ANTIBODIES THAT FIX THE LYMPHOCYTE ACTIVATION GEN 3 (LAG-3) AND ITS USES
US9616101B2 (en) 2012-07-06 2017-04-11 Kyoto Prefectural Public University Corporation Differentiation marker and differentiation control of eye cell
US9290489B2 (en) 2012-07-06 2016-03-22 Duke University Activation of TRPV4 ion channel by physical stimuli and critical role for TRPV4 in organ-specific inflammation and itch
HUE048947T2 (en) 2012-07-13 2020-09-28 Univ Pennsylvania Toxicity management for anti-tumor activity of cars
EP2889376A4 (en) 2012-08-24 2016-11-02 Chugai Pharmaceutical Co Ltd MOUSE Fc RII-SPECIFIC Fc ANTIBODY
SG11201500873XA (en) 2012-08-24 2015-04-29 Chugai Pharmaceutical Co Ltd Fcgriib-specific fc region variant
EP3552628A1 (en) 2012-09-07 2019-10-16 The Trustees Of Dartmouth College Vista modulators for diagnosis and treatment of cancer
JOP20200308A1 (en) 2012-09-07 2017-06-16 Novartis Ag IL-18 binding molecules
RU2673943C2 (en) 2012-09-27 2018-12-03 Чугаи Сейяку Кабусики Кайся Fgfr3 fusion gene and pharmaceutical drug targeting same
JP6284481B2 (en) 2012-09-28 2018-02-28 中外製薬株式会社 Evaluation method of blood coagulation reaction
EP2904115B1 (en) 2012-10-01 2018-08-08 Millennium Pharmaceuticals, Inc. Biomarkers and methods to predict response to inhibitors and uses thereof
UA118441C2 (en) 2012-10-08 2019-01-25 Протена Біосаєнсиз Лімітед Antibodies recognizing alpha-synuclein
CA2893794C (en) 2012-11-08 2021-11-09 University Of Miyazaki Antibody capable of specifically recognizing transferrin receptor
AU2013342163B2 (en) 2012-11-08 2018-08-16 F. Hoffmann-La Roche Ltd IL-6 antagonists and uses thereof
WO2014084859A1 (en) 2012-11-30 2014-06-05 Novartis Ag Molecules and methods for modulating tmem16a activities
SG11201503567SA (en) 2012-12-05 2015-06-29 Novartis Ag Compositions and methods for antibodies targeting epo
CN104995303A (en) 2012-12-18 2015-10-21 诺华股份有限公司 Compositions and methods that utilize a peptide tag that binds to hyaluronan
WO2014104165A1 (en) 2012-12-27 2014-07-03 中外製薬株式会社 Heterodimerized polypeptide
AU2013370171B2 (en) 2012-12-28 2018-09-13 Precision Biologics, Inc. Humanized monoclonal antibodies and methods of use for the diagnosis and treatment of colon and pancreas cancer
JO3519B1 (en) 2013-01-25 2020-07-05 Amgen Inc Antibody constructs for CDH19 and CD3
US9920121B2 (en) 2013-01-25 2018-03-20 Amgen Inc. Antibodies targeting CDH19 for melanoma
CA2900468C (en) 2013-02-06 2024-04-30 Inhibrx Llc Non-platelet depleting and non-red blood cell depleting cd47 antibodies and methods of use thereof
WO2015198217A2 (en) 2013-02-08 2015-12-30 Novartis Ag Compositions and methods for long-acting antibodies targeting il-17
SG11201505330QA (en) 2013-02-08 2015-08-28 Novartis Ag Anti-il-17a antibodies and their use in treating autoimmune and inflammatory disorders
AU2014217561B2 (en) 2013-02-13 2018-11-15 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Highly galactosylated anti-TNF-alpha antibodies and uses thereof
WO2014140927A2 (en) 2013-02-13 2014-09-18 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Proteins with modified glycosylation and methods of production thereof
US9458246B2 (en) 2013-03-13 2016-10-04 Amgen Inc. Proteins specific for BAFF and B7RP1
JOP20140087B1 (en) 2013-03-13 2021-08-17 Amgen Inc Proteins specific for baff and b7rp1 and uses thereof
CA2902026C (en) 2013-03-13 2023-08-29 Prothena Biosciences Limited Tau immunotherapy
PL2967012T3 (en) 2013-03-14 2021-04-19 Erasmus University Medical Center Rotterdam Transgenic non-human mammal for antibody production
EP2970479B1 (en) 2013-03-14 2019-04-24 Novartis AG Antibodies against notch 3
EP2970446A1 (en) 2013-03-15 2016-01-20 Amgen Research (Munich) GmbH Antibody constructs for influenza m2 and cd3
GB2525568B (en) 2013-03-15 2020-10-14 Abvitro Llc Single cell barcoding for antibody discovery
AR095596A1 (en) 2013-03-15 2015-10-28 Amgen Res (Munich) Gmbh UNIQUE CHAIN UNION MOLECULES UNDERSTANDING N-TERMINAL ABP
US9788534B2 (en) 2013-03-18 2017-10-17 Kymab Limited Animal models and therapeutic molecules
US10598674B2 (en) 2013-03-20 2020-03-24 Sphingotec Gmbh Adrenomedullin to guide therapy of blood pressure decline
MX2015014017A (en) 2013-04-02 2016-02-10 Chugai Pharmaceutical Co Ltd Fc region variant.
US9783618B2 (en) 2013-05-01 2017-10-10 Kymab Limited Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics
US11707056B2 (en) 2013-05-02 2023-07-25 Kymab Limited Animals, repertoires and methods
US9783593B2 (en) 2013-05-02 2017-10-10 Kymab Limited Antibodies, variable domains and chains tailored for human use
CN105264381B (en) 2013-05-16 2018-06-01 国立大学法人京都大学 For determining the method for cancer prognosis
WO2014186878A1 (en) 2013-05-24 2014-11-27 Cashman Neil R Cell senescence markers as diagnostic and therapeutic targets
EP3009518B1 (en) 2013-06-11 2020-08-12 National Center of Neurology and Psychiatry Method for predicting post-therapy prognosis of relapsing-remitting multiple sclerosis (rrms) patient, and method for determining applicability of novel therapy
AR096601A1 (en) 2013-06-21 2016-01-20 Novartis Ag ANTIBODIES OF LEXINED OXIDATED LDL RECEIVER 1 AND METHODS OF USE
TW201542591A (en) 2013-06-24 2015-11-16 Chugai Pharmaceutical Co Ltd Therapeutic agent comprising humanized anti-epiregulin antibody as active ingredient for non-small-cell lung carcinoma excluding adenocarcinoma
EP3013422A1 (en) 2013-06-28 2016-05-04 Amgen Inc. Methods for treating homozygous familial hypercholesterolemia
WO2015003114A1 (en) 2013-07-05 2015-01-08 University Of Washington Through Its Center For Commercialization Soluble mic neutralizing monoclonal antibody for treating cancer
US10208125B2 (en) 2013-07-15 2019-02-19 University of Pittsburgh—of the Commonwealth System of Higher Education Anti-mucin 1 binding agents and uses thereof
AU2014306564B2 (en) 2013-08-14 2019-10-17 Antlera Therapeutics Inc. Antibodies against frizzled proteins and methods of use thereof
WO2015022658A2 (en) 2013-08-14 2015-02-19 Novartis Ag Methods of treating sporadic inclusion body myositis
US10702608B2 (en) 2013-09-08 2020-07-07 Kodiak Sciences Inc. Factor VIII zwitterionic polymer conjugates
US20160229922A1 (en) 2013-09-20 2016-08-11 Chugai Seiyaku Kabushiki Kaisha Treatment for hemorrhagic diseases by anti-protein-c antibody
DK3050896T3 (en) 2013-09-27 2021-07-19 Chugai Pharmaceutical Co Ltd Process for the preparation of a polypeptide heteromultimer
TW201546284A (en) 2013-10-01 2015-12-16 Kymab Ltd Animal models and therapeutic molecules
JPWO2015068847A1 (en) 2013-11-11 2017-03-09 中外製薬株式会社 Antigen-binding molecules comprising modified antibody variable regions
CN105980557B (en) 2013-12-04 2020-04-07 中外制药株式会社 Antigen binding molecules with variable antigen binding capacity depending on concentration of compound and libraries thereof
US9914769B2 (en) 2014-07-15 2018-03-13 Kymab Limited Precision medicine for cholesterol treatment
US9067998B1 (en) 2014-07-15 2015-06-30 Kymab Limited Targeting PD-1 variants for treatment of cancer
US8980273B1 (en) 2014-07-15 2015-03-17 Kymab Limited Method of treating atopic dermatitis or asthma using antibody to IL4RA
US9023359B1 (en) 2014-07-15 2015-05-05 Kymab Limited Targeting rare human PCSK9 variants for cholesterol treatment
US9051378B1 (en) 2014-07-15 2015-06-09 Kymab Limited Targeting rare human PCSK9 variants for cholesterol treatment
US8883157B1 (en) 2013-12-17 2014-11-11 Kymab Limited Targeting rare human PCSK9 variants for cholesterol treatment
US9045548B1 (en) 2014-07-15 2015-06-02 Kymab Limited Precision Medicine by targeting rare human PCSK9 variants for cholesterol treatment
US8986691B1 (en) 2014-07-15 2015-03-24 Kymab Limited Method of treating atopic dermatitis or asthma using antibody to IL4RA
US8945560B1 (en) 2014-07-15 2015-02-03 Kymab Limited Method of treating rheumatoid arthritis using antibody to IL6R
US9045545B1 (en) 2014-07-15 2015-06-02 Kymab Limited Precision medicine by targeting PD-L1 variants for treatment of cancer
US8992927B1 (en) 2014-07-15 2015-03-31 Kymab Limited Targeting human NAV1.7 variants for treatment of pain
US8986694B1 (en) 2014-07-15 2015-03-24 Kymab Limited Targeting human nav1.7 variants for treatment of pain
US9017678B1 (en) 2014-07-15 2015-04-28 Kymab Limited Method of treating rheumatoid arthritis using antibody to IL6R
US9034332B1 (en) 2014-07-15 2015-05-19 Kymab Limited Precision medicine by targeting rare human PCSK9 variants for cholesterol treatment
SG11201605200XA (en) 2013-12-24 2016-07-28 Janssen Pharmaceutica Nv Anti-vista antibodies and fragments
US11014987B2 (en) 2013-12-24 2021-05-25 Janssen Pharmaceutics Nv Anti-vista antibodies and fragments, uses thereof, and methods of identifying same
TWI787590B (en) 2013-12-27 2022-12-21 日商中外製藥股份有限公司 Purification method of antibody with low isoelectric point
DK3087986T3 (en) 2013-12-27 2019-12-02 Chugai Pharmaceutical Co Ltd MUTANT FGFR GATEKEEPERGEN AND ACTIVE SUBSTANCE AIMED AT THE SAME
EP3092491B1 (en) 2014-01-07 2018-10-31 Bioatla, LLC Proteins targeting orthologs
WO2015121383A1 (en) 2014-02-12 2015-08-20 Michael Uhlin Bispecific antibodies for use in stem cell transplantation
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
TW201623331A (en) 2014-03-12 2016-07-01 普羅帝納生物科學公司 Anti-MCAM antibodies and associated methods of use
KR20160131073A (en) 2014-03-12 2016-11-15 프로테나 바이오사이언시즈 리미티드 Anti-laminin4 antibodies specific for lg4-5
EP3116911B8 (en) 2014-03-12 2019-10-23 Prothena Biosciences Limited Anti-mcam antibodies and associated methods of use
CA2938931A1 (en) 2014-03-12 2015-09-17 Prothena Biosciences Limited Anti-laminin4 antibodies specific for lg1-3
NZ724815A (en) 2014-04-04 2017-11-24 Bionomics Inc Humanized antibodies that bind lgr5
TW201622746A (en) 2014-04-24 2016-07-01 諾華公司 Methods of improving or accelerating physical recovery after surgery for hip fracture
JP6449338B2 (en) 2014-06-06 2019-01-09 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Antibodies against glucocorticoid-induced tumor necrosis factor receptor (GITR) and uses thereof
JP6997619B2 (en) 2014-06-11 2022-01-17 キャシー・エイ・グリーン Use of VISTA agonists and VISTA antagonists for suppression or enhancement of humoral immunity
TWI695011B (en) 2014-06-18 2020-06-01 美商梅爾莎納醫療公司 Monoclonal antibodies against her2 epitope and methods of use thereof
TWI831106B (en) 2014-06-20 2024-02-01 日商中外製藥股份有限公司 Pharmaceutical compositions for the prevention and/or treatment of diseases that develop and/or progress due to reduced or deficient activity of coagulation factor VIII and/or activated coagulation factor VIII
US20170290876A1 (en) 2014-06-25 2017-10-12 Novartis Ag Compositions and methods for long acting proteins
EP3160991A2 (en) 2014-06-25 2017-05-03 Novartis AG Compositions and methods for long acting proteins
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
CN107073297B (en) 2014-07-08 2021-09-14 纽约大学 Tau imaging ligands and their use in diagnosis and treatment of tauopathies
US9139648B1 (en) 2014-07-15 2015-09-22 Kymab Limited Precision medicine by targeting human NAV1.9 variants for treatment of pain
US9150660B1 (en) 2014-07-15 2015-10-06 Kymab Limited Precision Medicine by targeting human NAV1.8 variants for treatment of pain
AR101669A1 (en) 2014-07-31 2017-01-04 Amgen Res (Munich) Gmbh ANTIBODY CONSTRUCTS FOR CDH19 AND CD3
CA2956471A1 (en) 2014-07-31 2016-02-04 Amgen Research (Munich) Gmbh Optimized cross-species specific bispecific single chain antibody constructs
US20170275373A1 (en) 2014-07-31 2017-09-28 Amgen Research (Munich) Gmbh Bispecific single chain antibody construct with enhanced tissue distribution
JP6692343B2 (en) 2014-08-01 2020-05-13 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル Anti-CD45RC antibody for use as a drug
AP2017009721A0 (en) 2014-08-07 2017-01-31 Novartis Ag Angiopoietin-like 4 antibodies and methods of use
WO2016020882A2 (en) 2014-08-07 2016-02-11 Novartis Ag Angiopoetin-like 4 (angptl4) antibodies and methods of use
JP6858559B2 (en) 2014-08-20 2021-04-14 中外製薬株式会社 Method for measuring viscosity of protein solution
WO2016028325A1 (en) 2014-08-22 2016-02-25 Duke University Trpa1 and trpv4 inhibitors and methods of using the same for organ-specific inflammation and itch
US20160075772A1 (en) 2014-09-12 2016-03-17 Regeneron Pharmaceuticals, Inc. Treatment of Fibrodysplasia Ossificans Progressiva
SG10201911069WA (en) 2014-09-15 2020-01-30 Abvitro Llc High-throughput nucleotide library sequencing
KR20170054478A (en) 2014-09-16 2017-05-17 유나이티드 바이오메디칼 인크. Treatment and functional cure of hiv infection by monoclonal antibodies to cd4 mediating competitive hiv entry inhibition
MA40764A (en) 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd THERAPEUTIC AGENT INDUCING CYTOTOXICITY
WO2016059220A1 (en) 2014-10-16 2016-04-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Tcr-activating agents for use in the treatment of t-all
CN107208076A (en) 2014-10-17 2017-09-26 科达制药 Butyrylcholine esterase amphoteric ion polymer conjugate
WO2016073401A1 (en) 2014-11-03 2016-05-12 Bristol-Myers Squibb Company Use of caprylic acid precipitation for protein purification
IL251858B (en) 2014-11-07 2022-09-01 Eleven Biotherapeutics Inc Improved il-6 antibodies
WO2016073894A1 (en) 2014-11-07 2016-05-12 Eleven Biotherapeutics, Inc. Therapeutic agents with increased ocular retention
CA2968357A1 (en) 2014-11-21 2016-05-26 Bristol-Myers Squibb Company Antibodies against cd73 and uses thereof
JP2018505911A (en) 2014-12-05 2018-03-01 イミュネクスト，インコーポレーテッド Identification of VSIG8 as a putative VISTA receptor and its use to produce a VISTA / VSIG8 modulator
UY36449A (en) 2014-12-19 2016-07-29 Novartis Ag COMPOSITIONS AND METHODS FOR ANTIBODIES DIRECTED TO BMP6
TN2017000267A1 (en) 2014-12-23 2018-10-19 Bristol Myers Squibb Co Antibodies to tigit
US11229628B2 (en) 2015-01-09 2022-01-25 Duke University TRPA1 and TRPV4 inhibitors and methods of using the same for organ-specific inflammation and itch
TWI769570B (en) 2015-01-28 2022-07-01 愛爾蘭商普羅佘納生物科技有限公司 Anti-transthyretin antibodies
TWI718122B (en) 2015-01-28 2021-02-11 愛爾蘭商普羅佘納生物科技有限公司 Anti-transthyretin antibodies
TWI718121B (en) 2015-01-28 2021-02-11 愛爾蘭商普羅佘納生物科技有限公司 Anti-transthyretin antibodies
CA2974547A1 (en) 2015-02-05 2016-08-11 Chugai Seiyaku Kabushiki Kaisha Antibodies comprising an ion concentration dependent antigen-binding domain, fc region variants, il-8-binding antibodies, and uses thereof
KR101892883B1 (en) 2015-02-27 2018-10-05 추가이 세이야쿠 가부시키가이샤 Composition for treating il-6-related diseases
EA035635B1 (en) 2015-03-13 2020-07-17 Бристол-Маерс Сквибб Компани Use of alkaline washes during chromatography to remove impurities
WO2016153978A1 (en) 2015-03-20 2016-09-29 Bristol-Myers Squibb Company Use of dextran to enhance protein purification by affinity chromatography
WO2016153983A1 (en) 2015-03-20 2016-09-29 Bristol-Myers Squibb Company Use of dextran for protein purification
EP3283099B1 (en) 2015-04-17 2022-03-02 F. Hoffmann-La Roche AG Combination therapy with coagulation factors and multispecific antibodies
DK3283524T3 (en) 2015-04-17 2023-05-30 Amgen Res Munich Gmbh BISPECIFIC ANTIBODY CONSTRUCTIONS AGAINST CDH3 and CD3
CN107709359A (en) 2015-04-24 2018-02-16 加利福尼亚大学董事会 The conditioning agent that ROR1 ROR2 are combined
WO2016176341A1 (en) 2015-04-29 2016-11-03 Regeneron Pharmaceuticals, Inc. Treatment of fibrodysplasia ossificans progressiva
ES2936317T3 (en) 2015-05-29 2023-03-16 Bristol Myers Squibb Co Antibodies against OX40 and uses thereof
CN107614526A (en) 2015-06-05 2018-01-19 诺华股份有限公司 Target the antibody and its method of BMP 9 (BMP9)
DK3313882T3 (en) 2015-06-24 2020-05-11 Janssen Pharmaceutica Nv Anti-VISTA antibodies and fragments
EP3313886A1 (en) 2015-06-29 2018-05-02 The Rockefeller University Antibodies to cd40 with enhanced agonist activity
JO3711B1 (en) 2015-07-13 2021-01-31 H Lundbeck As Antibodies specific for hyperphosphorylated tau and methods of use thereof
TWI717375B (en) 2015-07-31 2021-02-01 德商安美基研究（慕尼黑）公司 Antibody constructs for cd70 and cd3
TWI829617B (en) 2015-07-31 2024-01-21 德商安美基研究（慕尼黑）公司 Antibody constructs for flt3 and cd3
TWI744242B (en) 2015-07-31 2021-11-01 德商安美基研究（慕尼黑）公司 Antibody constructs for egfrviii and cd3
TWI796283B (en) 2015-07-31 2023-03-21 德商安美基研究（慕尼黑）公司 Antibody constructs for msln and cd3
TW202346349A (en) 2015-07-31 2023-12-01 德商安美基研究（慕尼黑）公司 Antibody constructs for dll3 and cd3
AU2016303545B2 (en) 2015-08-03 2019-09-12 Novartis Ag Methods of treating FGF21-associated disorders
CA2997179A1 (en) 2015-09-02 2017-03-09 The Regents Of The Unversity Of Colorado, A Body Corporate Compositions and methods for modulating t-cell mediated immune response
WO2017042701A1 (en) 2015-09-09 2017-03-16 Novartis Ag Thymic stromal lymphopoietin (tslp)-binding antibodies and methods of using the antibodies
KR20180042433A (en) 2015-09-09 2018-04-25 노파르티스 아게 Use of thymus substrate lymphopoietin (TSLP) -binding antibodies and antibodies
EP3350226A2 (en) 2015-09-16 2018-07-25 Prothena Biosciences Limited Use of anti-mcam antibodies for treatment or prophylaxis of giant cell arteritis, polymyalgia rheumatica or takayasu's arteritis
WO2017046774A2 (en) 2015-09-16 2017-03-23 Prothena Biosciences Limited Use of anti-mcam antibodies for treatment or prophylaxis of giant cell arteritis, polymyalgia rheumatica or takayasu's arteritis
CA2993423C (en) 2015-09-18 2024-03-12 Chugai Seiyaku Kabushiki Kaisha Il-8-binding antibodies and uses thereof
ES2928681T3 (en) 2015-09-24 2022-11-21 Abvitro Llc Affinity-oligonucleotide conjugates and uses thereof
WO2018057051A1 (en) 2016-09-24 2018-03-29 Abvitro Llc Affinity-oligonucleotide conjugates and uses thereof
CN113774495A (en) 2015-09-25 2021-12-10 阿布维特罗有限责任公司 High throughput method for T cell receptor targeted identification of naturally paired T cell receptor sequences
JP6869553B2 (en) 2015-10-30 2021-05-12 ギャラクシー バイオテック， エルエルシーＧａｌａｘｙ Ｂｉｏｔｅｃｈ， Ｌｌｃ Very strong antibody that binds to death receptor 4 and death receptor 5.
US11649293B2 (en) 2015-11-18 2023-05-16 Chugai Seiyaku Kabushiki Kaisha Method for enhancing humoral immune response
WO2017086367A1 (en) 2015-11-18 2017-05-26 中外製薬株式会社 Combination therapy using t cell redirection antigen binding molecule against cell having immunosuppressing function
WO2017087678A2 (en) 2015-11-19 2017-05-26 Bristol-Myers Squibb Company Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereof
JP6983779B2 (en) 2015-11-30 2021-12-17 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニアThe Regents Of The University Of California Tumor-specific payload delivery and immune activation using human antibodies targeting highly specific tumor cell surface antigens
EP3383903A1 (en) 2015-11-30 2018-10-10 Bristol-Myers Squibb Company Anti human ip-10 antibodies and their uses
EA201891366A1 (en) 2015-12-09 2018-12-28 Корвус Фармасьютикалз, Инк. HUMANIZED ANTIBODIES AGAINST CD73
CA3008102A1 (en) 2015-12-18 2017-06-22 Novartis Ag Antibodies targeting cd32b and methods of use thereof
EP3395835B1 (en) 2015-12-25 2021-02-03 Chugai Seiyaku Kabushiki Kaisha Antibody having enhanced activity, and method for modifying same
US11066465B2 (en) 2015-12-30 2021-07-20 Kodiak Sciences Inc. Antibodies and conjugates thereof
EP3405492B1 (en) 2016-01-21 2020-10-21 Novartis AG Multispecific molecules targeting cll-1
CR20180418A (en) 2016-02-03 2019-01-15 Amgen Res Munich Gmbh BISPECPIFYING ANTIBODY STRUCTURES FOR PSMA AND CD3 THAT ARE LINKED TO T-CELLS
EA039859B1 (en) 2016-02-03 2022-03-21 Эмджен Рисерч (Мюник) Гмбх Bispecific antibody constructs binding egfrviii and cd3
CA3010704A1 (en) 2016-02-03 2017-08-10 Amgen Research (Munich) Gmbh Bcma and cd3 bispecific t cell engaging antibody constructs
CA3014013A1 (en) 2016-02-12 2017-08-17 Janssen Pharmaceutica Nv Anti-vista (b7h5) antibodies
EP3419599A4 (en) 2016-02-23 2019-09-11 Sesen Bio, Inc. Il-6 antagonist formulations and uses thereof
WO2017149513A1 (en) 2016-03-03 2017-09-08 Prothena Biosciences Limited Anti-mcam antibodies and associated methods of use
IL261602B2 (en) 2016-03-04 2024-06-01 Univ Rockefeller Antibodies to cd40 with enhanced agonist activity
MX2018010473A (en) 2016-03-04 2018-09-28 Squibb Bristol Myers Co Combination therapy with anti-cd73 antibodies.
WO2017152088A1 (en) 2016-03-04 2017-09-08 JN Biosciences, LLC Antibodies to tigit
WO2017153955A1 (en) 2016-03-09 2017-09-14 Prothena Biosciences Limited Use of anti-mcam antibodies for treatment or prophylaxis of granulomatous lung diseases
WO2017153953A1 (en) 2016-03-09 2017-09-14 Prothena Biosciences Limited Use of anti-mcam antibodies for treatment or prophylaxis of granulomatous lung diseases
MX2018010988A (en) 2016-03-14 2019-01-21 Chugai Pharmaceutical Co Ltd Cell injury inducing therapeutic drug for use in cancer therapy.
JP7034489B2 (en) 2016-03-15 2022-03-14 アイタブメッド （エイチケイ） リミテッド Multispecific Fab fusion protein and its use
KR102413037B1 (en) 2016-03-15 2022-06-23 메르사나 테라퓨틱스, 인코포레이티드 NAPI2B Targeted Antibody-Drug Conjugates and Methods of Using Same
KR20220004226A (en) 2016-03-22 2022-01-11 바이오노믹스 리미티드 Administration of an anti-lgr5 monoclonal antibody
CA3020364A1 (en) 2016-04-07 2017-10-12 Duke University Small molecule dual-inhibitors of trpv4 and trpa1 for sanitizing and anesthetizing
RU2746994C2 (en) 2016-04-15 2021-04-23 Иммьюнекст Инк. Human vista antibodies and their application
JOP20170091B1 (en) 2016-04-19 2021-08-17 Amgen Res Munich Gmbh Administration of a bispecific construct binding to CD33 and CD3 for use in a method for the treatment of myeloid leukemia
US20190145981A1 (en) 2016-04-21 2019-05-16 Sphingotec Therapeutics Gmbh Methods for determining dpp3 and therapeutic methods
SG11201809331RA (en) 2016-05-02 2018-11-29 Prothena Biosciences Ltd Antibodies recognizing tau
CN109219615B (en) 2016-05-02 2022-12-09 普罗塞纳生物科学有限公司 Antibodies recognizing TAU
AU2017264578A1 (en) 2016-05-09 2019-01-03 Bristol-Myers Squibb Company TL1A antibodies and uses thereof
WO2017208210A1 (en) 2016-06-03 2017-12-07 Prothena Biosciences Limited Anti-mcam antibodies and associated methods of use
JP7070932B2 (en) 2016-06-06 2022-05-18 シティ・オブ・ホープ BAFF-R Targeted Chimeric Antigen Receptor Modified T Cells and Their Use
JP7275446B2 (en) 2016-06-06 2023-05-18 シティ・オブ・ホープ BAFF-R antibody and uses thereof
WO2017216724A1 (en) 2016-06-15 2017-12-21 Novartis Ag Methods for treating disease using inhibitors of bone morphogenetic protein 6 (bmp6)
MA45493A (en) 2016-06-27 2019-05-01 Aicuris Anti Infective Cures Gmbh HCMC ENTRY INHIBITORS.
WO2018007922A2 (en) 2016-07-02 2018-01-11 Prothena Biosciences Limited Anti-transthyretin antibodies
WO2018007924A2 (en) 2016-07-02 2018-01-11 Prothena Biosciences Limited Anti-transthyretin antibodies
JP7016470B2 (en) 2016-07-02 2022-02-07 プロセナ バイオサイエンシーズ リミテッド Anti-transthyretin antibody
SG11201900133WA (en) 2016-07-08 2019-02-27 Sphingotec Gmbh Adrenomedullin for assessing congestion in a subject with acute heart failure
EP3878864A1 (en) 2016-07-12 2021-09-15 H. Lundbeck A/S Antibodies specific for hyperphosphorylated tau and methods of use thereof
CN117683135A (en) 2016-07-14 2024-03-12 百时美施贵宝公司 Antibodies against TIM3 and uses thereof
JP2019528312A (en) 2016-08-07 2019-10-10 ノバルティス アーゲー mRNA-mediated immunization methods
US10947268B2 (en) 2016-08-12 2021-03-16 Bristol-Myers Squibb Company Methods of purifying proteins
CA3033728A1 (en) 2016-08-13 2018-02-22 Ubi Ip Holdings Treatment and sustained virologic remission of hiv infection by antibodies to cd4 in haart stabilized patients
WO2018044970A1 (en) 2016-08-31 2018-03-08 University Of Rochester Human monoclonal antibodies to human endogenous retrovirus k envelope (herv-k) and uses thereof
IL265144B2 (en) 2016-09-06 2024-10-01 Chugai Pharmaceutical Co Ltd Methods of using a bispecific antibody that recognizes coagulation factor ix and/or activated coagulation factor ix and coagulation factor x and/or activated coagulation factor x
TW201825511A (en) 2016-09-09 2018-07-16 美商艾斯合顧問有限公司 Oncolytic virus expressing immune checkpoint modulators
EP3534947A1 (en) 2016-11-03 2019-09-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
LT3766343T (en) * 2016-11-04 2022-06-10 Regeneron Pharmaceuticals, Inc. Non-human animals having an engineered immunoglobulin lambda light chain locus
EP3538551A4 (en) 2016-11-10 2020-11-11 Fortis Therapeutics, Inc. Cd46-specific effector cells and uses thereof
WO2018087720A1 (en) 2016-11-14 2018-05-17 Novartis Ag Compositions, methods, and therapeutic uses related to fusogenic protein minion
KR102533814B1 (en) 2016-11-28 2023-05-19 추가이 세이야쿠 가부시키가이샤 Ligand-binding molecules capable of tunable ligand-binding activity
EP3339324A1 (en) 2016-12-22 2018-06-27 sphingotec GmbH Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in intervention and therapy of congestion in a patient in need thereof
RU2762059C2 (en) 2016-12-16 2021-12-15 Адреномед Аг Antibody against adrenomedullin (adm), or fragment of anti-adm antibody, or anti-adm non-ig frame for use in intervention and therapy of hyperemia in patient
TW201833140A (en) 2017-01-09 2018-09-16 美商莫瑞麥克製藥公司 Anti-fgfr antibodies and methods of use
JOP20190189A1 (en) 2017-02-02 2019-08-01 Amgen Res Munich Gmbh Low ph pharmaceutical composition comprising t cell engaging antibody constructs
US10899844B2 (en) 2017-02-08 2021-01-26 Novartis Ag FGF21 mimetic antibodies and uses thereof
US11142570B2 (en) 2017-02-17 2021-10-12 Bristol-Myers Squibb Company Antibodies to alpha-synuclein and uses thereof
US11492399B2 (en) 2017-03-24 2022-11-08 Zenyaku Kogyo Co., Ltd. Anti-IgM/B cell surface antigen bispecific antibody
RU2019129858A (en) 2017-03-24 2021-03-23 Новартис Аг METHODS FOR PREVENTION AND TREATMENT OF HEART DISEASES
KR20230148855A (en) 2017-03-30 2023-10-25 더 존스 홉킨스 유니버시티 A supramolecular high affinity protein-binding system for purification of biomacromolecules
US20210107994A1 (en) 2017-03-31 2021-04-15 Public University Corporation Nara Medical University Medicinal composition usable for preventing and/or treating blood coagulation factor ix abnormality, comprising multispecific antigen binding molecule replacing function of blood coagulation factor viii
TWI788340B (en) 2017-04-07 2023-01-01 美商必治妥美雅史谷比公司 Anti-icos agonist antibodies and uses thereof
EP3610010A4 (en) 2017-04-14 2021-02-24 Kodiak Sciences Inc. Complement factor d antagonist antibodies and conjugates thereof
JP7261739B2 (en) 2017-04-27 2023-04-20 中外製薬株式会社 Blood Coagulation Factor IX with Improved Pharmacokinetics
WO2018203545A1 (en) 2017-05-02 2018-11-08 国立研究開発法人国立精神・神経医療研究センター Method for predicting and evaluating therapeutic effect in diseases related to il-6 and neutrophils
BR112019022906A2 (en) 2017-05-02 2020-05-26 Prothena Biosciences Limited ANTIBODIES THAT RECOGNIZE TAU
WO2018204907A1 (en) 2017-05-05 2018-11-08 Amgen Inc. Pharmaceutical composition comprising bispecific antibody constructs for improved storage and administration
JP7308187B2 (en) 2017-05-26 2023-07-13 アブビトロ リミテッド ライアビリティ カンパニー High-throughput polynucleotide library sequencing and transcriptome analysis methods
KR102344616B1 (en) 2017-05-30 2021-12-31 더 보드 오브 리젠츠 오브 더 유니버시티 오브 오클라호마 Anti-Double Cortin-Like Kinase 1 Antibodies and Methods of Use
WO2018229715A1 (en) 2017-06-16 2018-12-20 Novartis Ag Compositions comprising anti-cd32b antibodies and methods of use thereof
US20200199541A1 (en) 2017-06-16 2020-06-25 Imba - Institut Für Molekulare Biotechnologie Gmbh Blood vessel organoid, methods of producing and using said organoids
CA3063659A1 (en) 2017-06-28 2019-01-03 Novartis Ag Methods for preventing and treating urinary incontinence
US10894833B2 (en) 2017-07-20 2021-01-19 H. Lundbeck A/S Agents, uses and methods for treatment
US11745165B2 (en) 2017-08-18 2023-09-05 The Johns Hopkins University Supramolecular filamentous assemblies for protein purification
MA50079A (en) 2017-09-07 2020-07-15 Juno Therapeutics Inc METHODS FOR IDENTIFYING CELLULAR CHARACTERISTICS RELATING TO RESPONSES ASSOCIATED WITH CELL THERAPY
BR112020005450A2 (en) 2017-09-25 2020-09-29 Adrenomed Ag antiadrenomedullin binder (adm) for use in therapy or prevention of disease symptoms
SG11202002268XA (en) 2017-10-18 2020-04-29 Adrenomed Ag Therapy monitoring under treatment with an anti-adrenomedullin (adm) binder
US11692037B2 (en) 2017-10-20 2023-07-04 Hyogo College Of Medicine Anti-IL-6 receptor antibody-containing medicinal composition for preventing post-surgical adhesion
AU2018356441A1 (en) 2017-10-25 2020-04-16 4TEEN4 Pharmaceuticals GmbH DPP3 binder directed to and binding to specific DPP3-epitopes and its use in the prevention or treatment of diseases / acute conditions that are associated with oxidative stress
WO2019081983A1 (en) 2017-10-25 2019-05-02 Novartis Ag Antibodies targeting cd32b and methods of use thereof
SG11202004627WA (en) 2017-11-28 2020-06-29 Chugai Pharmaceutical Co Ltd Ligand-binding molecule having adjustable ligand-binding activity
WO2019109016A1 (en) 2017-12-01 2019-06-06 Millennium Pharmaceuticals, Inc. Biomarkers and methods for treatment with nae inhibitors
AR113491A1 (en) 2017-12-11 2020-05-06 Amgen Inc CONTINUOUS MANUFACTURING PROCESS FOR BI-SPECIFIC ANTIBODY PRODUCTS
EP3498293A1 (en) 2017-12-15 2019-06-19 Institut National De La Sante Et De La Recherche Medicale (Inserm) Treatment of monogenic diseases with an anti-cd45rc antibody
TWI817974B (en) 2017-12-28 2023-10-11 日商中外製藥股份有限公司 Cytotoxicity-inducing therapeutic agent
UY38041A (en) 2017-12-29 2019-06-28 Amgen Inc CONSTRUCTION OF BIESPECFIC ANTIBODY DIRECTED TO MUC17 AND CD3
AU2019207915A1 (en) 2018-01-12 2020-07-16 Amgen Inc. PAC1 antibodies and uses thereof
EP3737700A1 (en) 2018-01-12 2020-11-18 Bristol-Myers Squibb Company Antibodies against tim3 and uses thereof
EP3747469A4 (en) 2018-01-31 2022-03-23 Motokazu Kato Therapeutic agent for asthma containing il-6 inhibitor
WO2019150309A1 (en) 2018-02-02 2019-08-08 Hammack Scott Modulators of gpr68 and uses thereof for treating and preventing diseases
KR102717599B1 (en) 2018-02-08 2024-10-14 스핑고텍 게엠베하 Adrenomedullin (ADM) for the diagnosis and/or prognosis of dementia and anti-adrenomedullin combinations for use in the treatment or prevention of dementia
EP3758737A4 (en) 2018-03-02 2022-10-12 Kodiak Sciences Inc. Il-6 antibodies and fusion constructs and conjugates thereof
EP3768715A1 (en) 2018-03-23 2021-01-27 Bristol-Myers Squibb Company Antibodies against mica and/or micb and uses thereof
US20210009632A1 (en) 2018-03-29 2021-01-14 Bristol-Myers Squibb Company Methods of purifying monomeric monoclonal antibodies
EP3569614A1 (en) 2018-05-18 2019-11-20 Julius-Maximilians-Universität Würzburg Compounds and methods for the immobilization of myostatin-inhibitors on the extracellular matrix by transglutaminase
CN112512480B (en) 2018-05-21 2024-10-01 中外制药株式会社 Freeze-dried preparation enclosed in glass container
TW202015726A (en) 2018-05-30 2020-05-01 瑞士商諾華公司 Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies
EP3586865A1 (en) 2018-06-21 2020-01-01 Charité - Universitätsmedizin Berlin Complement anaphylatoxin binders and their use in treatment of a subject having an ocular wound and/or fibrosis
AU2019304526B2 (en) 2018-07-20 2024-09-19 Aicuris Gmbh & Co. Kg Methods for screening and identifying agents that inhibit or modulate the nuclear egress complex of herpesviruses
TW202021616A (en) 2018-07-30 2020-06-16 美商安進公司 Prolonged administration of a bispecific antibody construct binding to cd33 and cd3
CN112512581A (en) 2018-08-03 2021-03-16 安进研发（慕尼黑）股份有限公司 Antibody constructs directed against CLDN18.2 and CD3
US11548938B2 (en) 2018-08-21 2023-01-10 Quidel Corporation DbpA antibodies and uses thereof
CN112789050A (en) 2018-08-27 2021-05-11 阿菲姆德股份有限公司 Cryopreserved NK cells preloaded with antibody constructs
CN113056487A (en) 2018-09-18 2021-06-29 梅里麦克制药股份有限公司 anti-TNFR 2 antibodies and uses thereof
US10894824B2 (en) 2018-09-24 2021-01-19 Aerpio Pharmaceuticals, Inc. Multispecific antibodies that target HPTP-β (VE-PTP) and VEGF
CN112789058A (en) 2018-10-11 2021-05-11 安进公司 Downstream processing of bispecific antibody constructs
UY38407A (en) 2018-10-15 2020-05-29 Novartis Ag TREM2 STABILIZING ANTIBODIES
KR20210092769A (en) 2018-11-16 2021-07-26 브리스톨-마이어스 스큅 컴퍼니 Anti-NKG2A antibodies and uses thereof
WO2020112870A1 (en) 2018-11-28 2020-06-04 Forty Seven, Inc. Genetically modified hspcs resistant to ablation regime
US20220211798A1 (en) 2018-12-21 2022-07-07 4TEEN4 Pharmaceuticals GmbH Therapy guidance and/or therapy monitoring for a treatment with angiotensin-receptor-agonist and/or a precursor thereof
MX2021008796A (en) 2019-01-22 2021-11-12 Bristol Myers Squibb Co Antibodies against il-7r alpha subunit and uses thereof.
CN113329770A (en) 2019-01-24 2021-08-31 中外制药株式会社 Novel cancer antigen and antibody against said antigen
KR20210134705A (en) 2019-02-28 2021-11-10 각코우호우진 쥰텐도 Antibodies that bind to truncated variant Calreticulin, and drugs for diagnosis, prevention or treatment of myeloproliferative tumors
US20220281990A1 (en) 2019-03-01 2022-09-08 Merrimack Pharmaceuticals, Inc. Anti-tnfr2 antibodies and uses thereof
JP2022524588A (en) 2019-03-03 2022-05-09 プロセナ バイオサイエンシーズ リミテッド Tau recognition antibody
US20220153875A1 (en) 2019-03-19 2022-05-19 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule containing antigen-binding domain of which binding activity to antigen is changed depending on mta, and library for obtaining said antigen-binding domain
CN113646630B (en) 2019-03-29 2024-05-07 百时美施贵宝公司 Method for measuring hydrophobicity of chromatographic resin
KR20210149779A (en) 2019-04-10 2021-12-09 추가이 세이야쿠 가부시키가이샤 Purification method of Fc region modified antibody
CA3135694A1 (en) 2019-04-17 2020-10-22 Hiroshima University Therapeutic agent for urological cancer which is characterized by being administered with il-6 inhibitor and ccr2 inhibitor in combination
EP4023230A4 (en) 2019-06-05 2023-11-15 Chugai Seiyaku Kabushiki Kaisha Antibody cleavage site-binding molecule
PE20220489A1 (en) 2019-06-12 2022-04-07 Novartis Ag NATRIURETIC PEPTIDE 1 RECEPTOR ANTIBODIES AND METHODS OF USE
MX2021014644A (en) 2019-06-13 2022-04-06 Amgen Inc Automated biomass-based perfusion control in the manufacturing of biologics.
JP2022542890A (en) 2019-07-26 2022-10-07 アムジエン・インコーポレーテツド Anti-IL13 antigen binding protein
AU2020338818A1 (en) 2019-08-30 2022-03-31 4TEEN4 Pharmaceuticals GmbH Therapy guidance and/or therapy monitoring for treatment of shock
MX2022002981A (en) 2019-09-10 2022-04-06 Amgen Inc Purification method for bispecific antigen-binding polypeptides with enhanced protein l capture dynamic binding capacity.
TW202124446A (en) 2019-09-18 2021-07-01 瑞士商諾華公司 Combination therapies with entpd2 antibodies
JP2022548881A (en) 2019-09-18 2022-11-22 ノバルティス アーゲー ENTPD2 Antibodies, Combination Therapy and Methods of Using Antibodies and Combination Therapy
EP4041312A4 (en) 2019-10-10 2023-12-20 Kodiak Sciences Inc. Methods of treating an eye disorder
WO2021097344A1 (en) 2019-11-13 2021-05-20 Amgen Inc. Method for reduced aggregate formation in downstream processing of bispecific antigen-binding molecules
AU2020408213A1 (en) 2019-12-19 2022-06-23 Quidel Corporation Monoclonal antibody fusions
AR120832A1 (en) 2019-12-20 2022-03-23 Amgen Inc MULTISPECIFIC ANTIBODY CONSTRUCTS CD40 AGONISTS TARGETING MESOTHELIN FOR THE TREATMENT OF SOLID TUMORS
EP4081554A1 (en) 2019-12-27 2022-11-02 Affimed GmbH Method for the production of bispecific fcyriii x cd30 antibody construct
WO2021142191A1 (en) 2020-01-08 2021-07-15 Regeneron Pharmaceuticals, Inc. Treatment of fibrodysplasia ossificans progressiva
EP4093771A1 (en) 2020-01-22 2022-11-30 Amgen Research (Munich) GmbH Combinations of antibody constructs and inhibitors of cytokine release syndrome and uses thereof
EP3871689A1 (en) 2020-02-26 2021-09-01 sphingotec GmbH Anti-adm-antibodies binding to the free n-terminus for accelerated transition of adm-gly to bio-adm in patients with adm-gly/ bio-adm ratio above a threshold and combination with vitamin c
EP4111204A1 (en) 2020-02-27 2023-01-04 4TEEN4 Pharmaceuticals GmbH Dpp3 for therapy guidance, monitoring and stratification of nt-adm antibodies in patients with shock
JP2023515042A (en) 2020-02-27 2023-04-12 アドレノメト アクチェンゲゼルシャフト Anti-Adrenomedullin (ADM) Antibody or Anti-ADM Antibody Fragment or Anti-ADM Non-Ig Scaffold for Use in Treatment or Prevention of Shock
EP4110812A2 (en) 2020-02-27 2023-01-04 AdrenoMed AG Anti-adrenomedullin (adm) binder for use in therapy of patients in shock
TW202200615A (en) 2020-03-12 2022-01-01 美商安進公司 Method for treatment and prophylaxis of crs in patients
EP3922993A1 (en) 2020-06-12 2021-12-15 4TEEN4 Pharmaceuticals GmbH Dpp3 in patients infected with coronavirus
EP4121771A1 (en) 2020-03-16 2023-01-25 AdrenoMed AG Pro-adrenomedullin or fragment thereof in patients infected with corona virus and treatments with binder against adrenomedullin
BR112022017277A2 (en) 2020-03-16 2022-10-18 4TEEN4 Pharmaceuticals GmbH DPP3 IN PATIENTS INFECTED WITH CORONA VIRUS
CN115427454A (en) 2020-03-19 2022-12-02 安进公司 Antibodies against mucin 17 and uses thereof
JP7329288B2 (en) 2020-03-27 2023-08-18 株式会社PhotoQ3 Drugs to kill tumor cells
CN115379858A (en) 2020-04-06 2022-11-22 光爱科技公司 Medicinal product for killing tumor cells
JP2023106635A (en) 2020-04-17 2023-08-02 中外製薬株式会社 Bispecific antigen binding molecules and compositions related thereto, uses, kits and methods for producing compositions
WO2021220215A1 (en) 2020-05-01 2021-11-04 Novartis Ag Engineered immunoglobulins
WO2021220218A1 (en) 2020-05-01 2021-11-04 Novartis Ag Immunoglobulin variants
EP3909601A1 (en) 2020-05-11 2021-11-17 LeukoCom GmbH A novel antibody binding specifically to human ceacam1/3/5 and use thereof
US20230192867A1 (en) 2020-05-15 2023-06-22 Bristol-Myers Squibb Company Antibodies to garp
US20220017636A1 (en) 2020-05-19 2022-01-20 Amgen Inc. Mageb2 binding constructs
WO2021235537A1 (en) 2020-05-22 2021-11-25 中外製薬株式会社 Antibody for neutralizing substance having coagulation factor viii (f.viii) function-substituting activity
AU2021281554A1 (en) 2020-05-29 2022-12-15 Amgen Inc. Adverse effects-mitigating administration of a bispecific antibody construct binding to CD33 and CD3
IL298111A (en) 2020-06-02 2023-01-01 Arcus Biosciences Inc Antibodies to tigit
EP4171743A4 (en) 2020-06-24 2024-07-24 Prothena Biosciences Ltd Antibodies recognizing sortilin
JPWO2021261546A1 (en) 2020-06-24 2021-12-30
CA3186914A1 (en) 2020-07-28 2022-02-03 Masakazu Fukuda Prefilled syringe formulation with needle with needle shield containing novel modified antibody
CN116194124A (en) 2020-07-31 2023-05-30 中外制药株式会社 Pharmaceutical composition comprising cells expressing chimeric receptors
MX2023001625A (en) 2020-08-07 2023-05-16 Fortis Therapeutics Inc Immunoconjugates targeting cd46 and methods of use thereof.
BR112023003511A2 (en) 2020-08-27 2023-04-11 Meiji Seika Pharma Co Ltd BISPECIFIC ANTIBODY CALR-CD3 MUTANT ANTICLEAVAD AND PHARMACEUTICAL COMPOSITION
EP4225792A1 (en) 2020-10-08 2023-08-16 Affimed GmbH Trispecific binders
US20230406929A1 (en) 2020-11-06 2023-12-21 Amgen Inc. Polypeptide constructs binding to cd3
KR20230104256A (en) 2020-11-06 2023-07-07 암젠 인크 Multitargeting bispecific antigen binding molecules of increased selectivity
CN116472288A (en) 2020-11-06 2023-07-21 诺华股份有限公司 Antibody Fc variants
US20230406887A1 (en) 2020-11-06 2023-12-21 Amegen Inc. Antigen binding domain with reduced clipping rate
TW202233679A (en) 2020-11-06 2022-09-01 德商安美基研究（慕尼黑）公司 Polypeptide constructs selectively binding to cldn6 and cd3
EP4023218A1 (en) 2020-12-02 2022-07-06 S-Form Pharma Combination therapy for patients having acute and/or persistent dyspnea
US20240052042A1 (en) 2020-12-14 2024-02-15 Novartis Ag Reversal binding agents for anti-natriuretic peptide receptor i (npri) antibodies and uses thereof
CN117320749A (en) 2021-03-12 2023-12-29 中外制药株式会社 Pharmaceutical composition for treating or preventing myasthenia gravis
JP2024513376A (en) 2021-04-02 2024-03-25 アムジエン・インコーポレーテツド MAGEB2 binding construct
MX2023012931A (en) 2021-05-06 2023-11-13 Amgen Res Munich Gmbh Cd20 and cd22 targeting antigen-binding molecules for use in proliferative diseases.
WO2022265912A1 (en) 2021-06-16 2022-12-22 Gundersen Lutheran Medical Foundation, Inc. Antibodies targeting an amphiregulin-derived cell surface neo-epitope
JP2024529381A (en) 2021-07-30 2024-08-06 アフィメド ゲーエムベーハー Duplex Body
EP4144898A1 (en) 2021-09-07 2023-03-08 New/era/mabs GmbH Method for selecting or screening antibodies from an antibody library
WO2023048231A1 (en) 2021-09-24 2023-03-30 株式会社PhotoQ3 Medicine for killing tumor cells
WO2023057871A1 (en) 2021-10-04 2023-04-13 Novartis Ag Surfactant stabilizers
AU2022361184A1 (en) 2021-10-08 2024-05-09 Chugai Seiyaku Kabushiki Kaisha Method for preparing prefilled syringe formulation
WO2023078968A1 (en) 2021-11-03 2023-05-11 Affimed Gmbh Bispecific cd16a binders
WO2023079493A1 (en) 2021-11-03 2023-05-11 Affimed Gmbh Bispecific cd16a binders
MX2024006387A (en) 2021-12-01 2024-06-04 Chugai Pharmaceutical Co Ltd Method for preparing antibody-containing formulation.
CN118742324A (en) 2022-02-25 2024-10-01 学校法人顺天堂 Medicine formed by combining anti-mutation CALR antibody and other medicaments
WO2023175035A1 (en) 2022-03-15 2023-09-21 Adrenomed Ag Stable aqueous formulation of an anti-adrenomedullin (adm) antibody or anti-adm antibody fragment
AU2023259761A1 (en) 2022-04-26 2024-09-26 Novartis Ag Multispecific antibodies targeting il-13 and il-18
AU2023268600A1 (en) 2022-05-12 2024-11-07 Amgen Research (Munich) Gmbh Multichain multitargeting bispecific antigen-binding molecules of increased selectivity
WO2024023368A1 (en) 2022-07-29 2024-02-01 4TEEN4 Pharmaceuticals GmbH Prediction of an increase of dpp3 in a patient with septic shock
WO2024023369A1 (en) 2022-07-29 2024-02-01 Adrenomed Ag Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in therapy or prevention of shock
WO2024059675A2 (en) 2022-09-14 2024-03-21 Amgen Inc. Bispecific molecule stabilizing composition
EP4345109A1 (en) 2022-09-30 2024-04-03 AdrenoMed AG Anti-adrenomedullin (adm) binder for use in therapy of pediatric patients with congenital heart disease
WO2024126793A1 (en) 2022-12-15 2024-06-20 4TEEN4 Pharmaceuticals GmbH Dpp3 inhibitor for improvement of pulmonary function in critically ill patients
WO2024163477A1 (en) 2023-01-31 2024-08-08 University Of Rochester Immune checkpoint blockade therapy for treating staphylococcus aureus infections
WO2024194276A1 (en) 2023-03-17 2024-09-26 Pam Theragnostics Gmbh Methods for determining peptidylglycine alpha-amidating monooxygenase (pam) and its use for diagnostic purpose
WO2024200862A1 (en) 2023-03-29 2024-10-03 4TEEN4 Pharmaceuticals GmbH Dpp3 inhibitor for myocardial protection and prevention of myocardial injury in critically ill patients with blood pressure decline

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8823869D0 (en) * 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
WO1991000906A1 (en) * 1989-07-12 1991-01-24 Genetics Institute, Inc. Chimeric and transgenic animals capable of producing human antibodies
DK0463151T3 (en) * 1990-01-12 1996-07-01 Cell Genesys Inc Generation of xenogenic antibodies
DK0814159T3 (en) * 1990-08-29 2005-10-24 Genpharm Int Transgenic, non-human animals capable of forming heterologous antibodies

Also Published As

Publication number Publication date
AU3328493A (en) 1993-07-19
EP0746609A1 (en) 1996-12-11
JPH07503132A (en) 1995-04-06
JP2004008218A (en) 2004-01-15
CA2124967C (en) 2008-04-08
EP0746609A4 (en) 1997-12-17
WO1993012227A1 (en) 1993-06-24

Similar Documents

Publication Publication Date Title
CA2124967A1 (en) Transgenic non-human animals capable of producing heterologous antibodies
CA2089661A1 (en) Transgenic non-human animals capable of producing heterologous antibodies
JP2019076108A5 (en)
US10194645B2 (en) Mouse λ light chain locus
EP0854917A4 (en) Transgenic non-human animals capable of producing heterologous antibodies
WO2009097006A3 (en) Hco32 and hco27 and related examples
CA2161351A1 (en) Transgenic non-human animals capable of producing heterologous antibodies
WO2005007696A3 (en) Humanized immunoglobulin loci
EP0942959A4 (en) Transgenic non-human animals capable of producing heterologous antibodies
CA2430013A1 (en) Transgenic transchromosomal rodents for making human antibodies
RU2011102962A (en) PRODUCING ANTIBODIES MAMMALS, NOT A HUMAN
JP2020530760A5 (en)
JP2000502324A5 (en)
WO2002059263A3 (en) Transgenic animals comprising a humanized immune system
KR900702049A (en) Method for producing antibodies from transgenic animals
Lonberg et al. Ransgenic non-human animals for producing heterologous antibodies
CA3171186A1 (en) Transgenic animals expressing heavy chain antibodies
AU2003204055A1 (en) Transgenic non-human animals capable of producing heterologous antibodies
AU4190297A (en) Transgenic non-human animals capable of producing heterologous antibodies

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20121217